ASAM 53rd
ANNUAL
CONFERENCE
Innovations in Addiction Medicine and Science
March 31–April 3, 2022 | Hollywood, FL

FINAL PROGRAM
MAKE A SPLASH WITH ASAM

Pre-Conference Courses
Thursday, March 31, 2022

FREE WIFI SEE PAGE 3  |  FREE APP SEE PAGE 4
“Addiction medicine provides hope, healing, and the opportunity to change.”

DAVID KAN, MD, DFASAM
ASAM member since 2006
Welcome to Florida and the ASAM 53rd Annual Conference – Innovations in Addiction Medicine and Science! There are many opportunities to expand your horizons through engaging sessions, cutting-edge research and a full spectrum of addiction care content. Dive on in!

The 2022 program showcases robust offerings including three pre-conference courses, three general sessions, 113 scientific posters, and a wide variety of concurrent sessions. Plan to be inspired at the Opening Plenary, motivated at the Big Ideas Plenary, and enlightened at the Policy & Science Plenary as distinguished presenters discuss topics shaping the field of addiction medicine.

Unwind between sessions at one of the many fun-networking opportunities that await by the sea! Enjoy the Shell-brate Good Tides! Welcome Back Reception on Thursday evening. Friday join colleagues at the Ice Cream Social and the Happenin’ Havana Nights Party. Don’t forget to check out the Exhibit Hall during breaks to make meaningful connections for your practice!

Everyone is encouraged to attend the State of the Organization meeting on Saturday morning for important updates on ASAM activities, 2022 elections and more.

The Annual Conference Planning Committee, Pre-Course Planning Committees, presenters and ASAM staff have dedicated months of planning to create this exciting event. In order to ensure that everyone has the best possible experience, please be sure to adhere to posted health and safety guidelines. We hope you enjoy your time in the Sunshine State and connecting with old and new friends - “water you wading for”?

William F. Haning III, MD, DLFAPA, DFASAM
President, American Society of Addiction Medicine

Learning Objectives
At the conclusion of the conference, learners should be able to:
1. Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
2. Compare presented clinical guidelines/best practices with the participant’s current practice and identify strengths or gaps.
3. Analyze new research and science to develop practical applications for treatment or further research.
4. Explain recent and upcoming policy changes and identify implications or areas for provider involvement.
5. Create a network of professionals and a set of resources to support the participant’s practice.

Log-in for free WiFi!
Network: ASAM2022
Password: ASAM2022

www.TheASAMAnnualConference.org
Shell-Abrate Good Tides! Welcome Back Reception
Great Hall 1-3, Third Floor
Thursday, March 31 | 5:30 pm – 7:30 pm
Spend a sand-tastic evening diving in to your new surroundings and reconnecting with colleagues and exhibitors.

New Member & First Time Attendee Welcome Reception
Great Hall 6 Foyer, Third Floor
Thursday, March 31 | 5:30 pm – 6:30 pm
Get ready to make a big splash! Meet and greet with fellow first timers and allow the ASAM team to help you enjoy the conference.

Stretch Out the Stress! Morning Yoga
South Palm Court, First Floor
Friday, April 1 | 7:00 am – 8:00 am
Breathe in. Breathe out. Join your colleagues for a morning of downward-facing dogs and warrior poses. All levels are welcome and mats are provided.

Ice Cream Social
Great Hall 1-3, Third Floor
Friday, April 1 | 4:00 pm – 5:00 pm
Chat with colleagues and exhibitors over a delicious ice cream treat.

Happenin’ Havana Nights Party
Diplomat Landing, Across the SkyBridge
Friday, April 1 | 6:00 pm - 7:30 pm
Grab your fedora, put on festive party clothes, and join us by the scenic Intracoastal Waterway! You will be treated to South Florida’s famous Cuban food specialties and an amazing sunset. Feel the rhythm of the Danzón music while you party and have fun with colleagues and friends. No passport needed!

Lunch Bunch
Great Hall Foyer, Third Floor
Saturday, April 2 | 12:30 pm – 1:30 pm
Grab a bite and grab a seat! Meet people with your same interests, practice setting, profession, and career stage. Talk about topics that matter to you.

Post of the Day #ASAMAnnual2022
Use #ASAMAnnual2022 on Facebook, Instagram, and Twitter to share your best moments from the conference. Each day we will give a prize to the top Post of the Day!

Download the ASAM Events App
The ASAM Events App is your go-to guide for all ASAM conferences and courses.

Step 1: Download the ASAM Events App
- Go to the Apple App Store or Google Play and search for “ASAM Events.”
- Download the ASAM Events App and click “Open.”

Step 2: Open ASAM Annual 2022
- Once inside the ASAM Events App, click on “ASAM Annual 2022.”
- When prompted, create a new account to access this event.

App Features:
- View slides & posters
- Star your favorite, must-see sessions
- Take notes during presentations
- Stay up to date on conference info

Questions? Visit the ASAM Education Desk

TIPS
- Everyone will need to create a new account the first time they open the ASAM Annual 2022 event within the app. The new account does not need to have the same email address as was used during registration.
- If you want to log in to your account on multiple devices, use the password that was emailed to you after you created your account.
- To sync with updated conference info, locate the menu in the top right corner. Click “Refresh Schedule” in the “Your Event” section of the menu.
Don’t get lost at sea!
Use the keys on this page to customize your educational experience and get the most out of the ASAM Annual Conference.

Session Type

**Collaborative Sessions (CS)**
Developed in collaboration with a partner organization.

**Focus Sessions (FS)**
Provides an in-depth look at a specific scientific or clinical topic.

**General Sessions (GS)**
Offers unparalleled access to national leaders.

**Poster Sessions**
Features scientific research on physical posters.

**Workshop Session (WS)**
Uses highly interactive learning formats.

Session Icons

The icons below correspond with the addiction medicine core competencies and were self-identified by session presenters during the abstract submission process. Attendees can select sessions based on their addiction medicine competency needs.

<table>
<thead>
<tr>
<th>TITLE</th>
<th>ICON</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient Care</strong></td>
<td>![Icon]</td>
</tr>
<tr>
<td><strong>Medical Knowledge</strong></td>
<td>![Icon]</td>
</tr>
<tr>
<td><strong>Practice-Based Improvement</strong></td>
<td>![Icon]</td>
</tr>
<tr>
<td><strong>Interpersonal Skills</strong></td>
<td>![Icon]</td>
</tr>
<tr>
<td><strong>Professionalism</strong></td>
<td>![Icon]</td>
</tr>
<tr>
<td><strong>Systems Based Practice</strong></td>
<td>![Icon]</td>
</tr>
</tbody>
</table>

Attendees should also keep an eye out for this icon, which identifies sessions on the topic of health equity.

Session Experience Level

**Introductory** – appropriate for learners with limited knowledge or clinical experience on this topic.

**Intermediate** – appropriate for learners with some knowledge and clinical experience on this topic.

**Advanced** – appropriate for learners with extensive knowledge and clinical experience on this topic.

“The 2021 Conference offered lifesaving educational resources.”
### Pre-Conference Activities

**Tuesday, March 29, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 pm – 9:00 pm</td>
<td>Board of Directors Meeting</td>
<td>33rd Floor Lounge, 33rd Floor</td>
</tr>
</tbody>
</table>

**Wednesday, March 30, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am – 5:00 pm</td>
<td>Board of Directors Meeting</td>
<td>33rd Floor Lounge, 33rd Floor</td>
</tr>
<tr>
<td>5:00 pm – 6:00 pm</td>
<td>Fundamentals Workshop Faculty Meeting</td>
<td>317 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Motivational Interviewing Planning Committee Meeting</td>
<td>316 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Pain &amp; Addiction: Common Threads Course Faculty Meeting</td>
<td>319 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Ruth Fox Endowment Scholarship Recipients Meeting</td>
<td>303 Conference Room, Third Floor</td>
</tr>
<tr>
<td>5:00 pm – 8:00 pm</td>
<td>ASAM Registration &amp; Education Desk Open</td>
<td>Grand Ballroom Foyer, Second Floor</td>
</tr>
<tr>
<td>6:00 pm – 9:00 pm</td>
<td>Board of Directors Dinner <em>(By Invitation Only)</em></td>
<td>33rd Floor Lounge, 33rd Floor</td>
</tr>
<tr>
<td>9:00 pm – 10:00 pm</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
</tbody>
</table>

**Thursday, March 31, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 7:30 am</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>ASAM Registration &amp; Education Desk Open</td>
<td>Grand Ballroom Foyer, Second Floor</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Pre-Conference Course/Workshop Continental Breakfast</td>
<td>Pre-Conference Course/Workshop Rooms, Second Floor</td>
</tr>
<tr>
<td>8:00 am – 5:30 pm</td>
<td>ASAM Fundamentals of Addiction Medicine Workshop – <em>(8 CME)</em></td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>ASAM Motivational Interviewing Workshop – <em>(8 CME)</em></td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Pain &amp; Addiction: Common Threads XXIII Course – <em>(8 CME)</em></td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td>3:00 pm – 7:00 pm</td>
<td>ASAM Booth Open</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
</tbody>
</table>

**Annual Conference Begins**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 pm – 6:30 pm</td>
<td>New Member &amp; First Time Attendee Welcome Reception</td>
<td>Great Hall Foyer 6, Third Floor</td>
</tr>
<tr>
<td>5:30 pm – 7:30 pm</td>
<td>Exhibit Hall Open</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Shell-abrate Good Tides! Welcome Back Reception</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td>6:30 pm – 8:00 pm</td>
<td>President’s Ruth Fox Reception for Awardees and Donors <em>(By Invitation Only)</em></td>
<td>33rd Floor Lounge, 33rd Floor</td>
</tr>
<tr>
<td>7:30 pm – 8:30 pm</td>
<td>Becoming Certified in Addiction Medicine and How to Continue That Certification – <em>(1 CME)</em></td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Developing Addiction Medicine Fellowships – <em>(1 CME)</em></td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Navigating the Osteopathic Addiction Medicine Certification Exam – <em>(1 CME)</em></td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Child &amp; Adolescent Addiction Special Interest Group Meeting</td>
<td>Atlantic Ballroom 1, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Criminal Justice Special Interest Group Meeting</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Nicotine &amp; Tobacco Issues Special Interest Group Meeting</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Women &amp; SUDs Special Interest Group Meeting</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td>8:00 pm – 10:00 pm</td>
<td>Chapter Leadership &amp; Policy Roundtable Meeting</td>
<td>303 Conference Room, Third Floor</td>
</tr>
<tr>
<td>9:00 pm – 10:00 pm</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
</tbody>
</table>

The full conference schedule (including speaker information, presentation slides, and more) is available on the conference website (https://bit.ly/ASAM2022Schedule) and in the ASAM Events app.
### Friday, April 1, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 7:30 am</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Medical Toxicology Special Interest Group Meeting</td>
<td>Atlantic Ballroom 1, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Opioid Treatment Program Special Interest Group Meeting</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Physicians Health Program Special Interest Group Meeting</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Ruth Fox Endowment Scholarship Recipients Meeting</td>
<td>303 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Stretch Out the Stress! Morning Yoga</td>
<td>South Palm Court, First Floor</td>
</tr>
<tr>
<td>7:00 am – 6:00 pm</td>
<td>ASAM Registration &amp; Education Desk Open</td>
<td>Grand Ballroom Foyer, Second Floor</td>
</tr>
<tr>
<td>7:30 am – 8:30 am</td>
<td>Continental Breakfast</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>8:00 am – 5:00 pm</td>
<td>ASAM Booth Open</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>8:30 am – 10:00 am</td>
<td>Opening Scientific Plenary &amp; Distinguished Scientist Lecture – GS (1.5 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td>10:00 am – 10:30 am</td>
<td>Refreshment Break</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td>10:00 am – 5:00 pm</td>
<td>Speaker Meet &amp; Greet</td>
<td>ASAM Booth, Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>10:30 am – 11:30 am</td>
<td>Advances in Treatments for Methamphetamine Use Disorder – CS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Buprenorphine Dose Limits - What Is The Evidence? – FS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Cannabis Use in Pregnancy: Person-Centered Perspectives – FS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>How We Built This: Improving Treatment Access and Engagement for Hispanic/Latinx Patients – FS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Medication in Opioid Courts: Reducing Overdose Through Triage in Court Settings – FS (1 CME)</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Precipitated Withdrawal 2.0: Outpatient Tips and Tricks – WS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Tobacco Cessation: Evidence-based Guidelines for Practitioners – FS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td>11:30 am – 12:45 pm</td>
<td>Lunch Break</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Scientific Poster Session 1 – (1.5 CME)</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>12:00 pm – 12:30 pm</td>
<td>Social Workers &amp; Counselors Meet-Up</td>
<td>ASAM Booth, Great Hall Foyers, Third Floor</td>
</tr>
<tr>
<td>1:00 pm – 2:30 pm</td>
<td>Big Ideas Plenary - Operationalizing Racial Justice and Equity in Healthcare – GS (1.5 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td>2:30 pm – 3:00 pm</td>
<td>Networking Break</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td>3:00 pm – 4:00 pm</td>
<td>Addiction Medicine in Healthcare Education - Listening to Students and Facilitating Faculty – WS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>How to Implement Low-Dose Buprenorphine Initiation in Your Practice: A Case-Based Workshop – WS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Meeting People Where They Are: Corrections, Telehealth, and OUD – FS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Naloxone: What You Need to Know – FS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>The Next Chapter: A Discussion on the Next Edition of The ASAM Criteria – CS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Virtual is Now Reality: Telehealth to Deliver Care for Substance Use Disorders – WS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>4:00 pm – 4:45 pm</td>
<td>ASAM Fellows (FASAM) Meet-Up</td>
<td>ASAM Booth, Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>4:00 pm – 5:00 pm</td>
<td>Ice Cream Social</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td>5:00 pm – 6:00 pm</td>
<td>An Organizational Framework for Approaching Patients with OUD and Painful Serious Illness – WS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Drug Use in Hospital Settings: Why it Happens and How We Respond – WS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>History of the Stigma &amp; Criminalization of OUD and its Treatment – FS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Supporting Birthing People and Families During COVID; Tools for Buprenorphine and Methadone – WS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td></td>
<td>The Impact of COVID on Alcohol Use Disorder: Epidemiology and Treatment – CS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Treat Addiction, Save Lives; The History of the American Society of Addiction Medicine – FS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Widening the Net: Engaging Sexual and Gender Minority Youth in Addiction Treatment – WS (1 CME)</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td>6:00 pm – 7:30 pm</td>
<td>Happenin’ Havana Nights Party</td>
<td>Diplomat Landing, Across the Skybridge</td>
</tr>
<tr>
<td>7:30 pm – 8:30 pm</td>
<td>Addiction Consult Special Interest Group Meeting</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Annual Conference Program Planning Committee Meeting</td>
<td>319 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Journal of Addiction Medicine Editorial Meeting</td>
<td>316 Conference Room, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Primary Care &amp; Family Medicine Special Interest Group Meeting</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Twelve Step Recovery Special Interest Group Meeting</td>
<td>Atlantic Ballroom 1, Second Floor</td>
</tr>
<tr>
<td>9:00 pm – 10:00 pm</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
</tbody>
</table>

**Saturday, April 2, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 7:30 am</td>
<td>Mutual Help</td>
<td>302 Conference Room, Third Floor</td>
</tr>
<tr>
<td>7:00 am – 8:30 am</td>
<td>Continental Breakfast</td>
<td>Great Hall Foyers, Third Floor</td>
</tr>
<tr>
<td>7:00 am – 5:30 pm</td>
<td>ASAM Registration &amp; Education Desk Open</td>
<td>Grand Ballroom Foyer, Second Floor</td>
</tr>
<tr>
<td>7:45 am – 8:15 am</td>
<td>ASAM: State of the Organization</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td>8:00 am – 5:00 pm</td>
<td>ASAM Booth Open</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>8:30 am – 10:00 am</td>
<td>Policy &amp; Science Plenary Session - Expanding Access to Care Through Telehealth: Lessons Learned During the Pandemic – GS (1.5 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td>10:00 am – 11:30 am</td>
<td>Exhibit Hall Open</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Refreshment Break</td>
<td>Great Hall 1-3, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Scientific Poster Session 2 – (1.5 CME)</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>10:15 am – 11:15 am</td>
<td>Public Policy Committee Meeting</td>
<td>316 Conference Room, Third Floor</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>Beyond the Lecture: Leading and Engaging Learners in Addiction Medicine Education – WS (1 CME)</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Bridging the Gap Between Science and Clinical Practice in Addiction Medicine – CS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Cannabis: Products, Health Impact, Policies and Intervention – FS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Clinical Characterization of Kratom: Is it a Craze or Here to Stay? – FS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>Continuum of Micro-dosing: Applying a Novel Technique Across a Healthcare System – FS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Focus on Phenobarbital: Applications for Alcohol and Sedative-Hypnotic Withdrawal – FS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Population Health Approach to Opioid Use Disorder: Can It Change The Game? – FS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td>12:30 pm – 1:15 pm</td>
<td>Nurses, Nurse Practitioners, &amp; Physician Assistants Meet-Up</td>
<td>ASAM Booth, Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>12:30 pm – 1:30 pm</td>
<td>Lunch Bunch</td>
<td>Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>1:30 pm – 2:30 pm</td>
<td>Changes To Treatment Regulations During And After The COVID-19 Public Health Emergency – CS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Low-Dose Buprenorphine Inductions: Options and Innovations – WS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Mentoring Women Graduate Students Seeking a Career in Substance Use Disorder Research – FS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Opioid Use Disorder in the Perinatal Population: Reviewing Evidence-Based Care Models and Best Practices – WS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td></td>
<td>The Good, Bad and Ugly: Drug Testing in Liver Transplant Evaluations – FS (1 CME)</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>The Inner Work of Caring for Individuals with Severe Substance Use Disorders – WS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td>2:30 pm – 3:00 pm</td>
<td>Beach Break</td>
<td>Beachfront, First Floor</td>
</tr>
<tr>
<td>3:00 pm – 4:00 pm</td>
<td>5 Tips for Teaching Trainees about SUD in Integrated Clinic Settings – WS (1 CME)</td>
<td>Diplomat Ballroom 1&amp;2, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Alcohol Withdrawal Management: Beyond Benzos – FS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Annual Review of Addiction Medicine: Highest Impact Publications from 2021-2022 – FS (1 CME)</td>
<td>Great Hall 4-6, Third Floor</td>
</tr>
<tr>
<td></td>
<td>How iOAT Care Could Be Improved?: Providers Perspectives on Clients’ Needs – FS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Leveraging Community Harm Reduction Services to Provide Mobile Primary Care/SUD Treatment – FS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Methamphetamine Use Disorder in Pregnancy – FS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Palliative Care for Patients with Substance Use Disorders: Challenges and Opportunities – WS (1 CME)</td>
<td>Grand Ballroom West, Second Floor</td>
</tr>
<tr>
<td>4:00 pm – 4:30 pm</td>
<td>Refreshment Break</td>
<td>Grand Ballroom Foyer, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Students and Ruth Fox Scholars Meet-Up</td>
<td>ASAM Booth, Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td></td>
<td>Meet the JAM Editors</td>
<td>ASAM Booth, Great Hall Foyer, Third Floor</td>
</tr>
<tr>
<td>4:30 pm – 5:30 pm</td>
<td>Development of The ASAM Criteria Intake Assessment: A Free, Paper-Based, Interview Form – FS (1 CME)</td>
<td>Atlantic Ballroom 2&amp;3, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Extended-Release Buprenorphine: Pearls, Protocols and Possibilities from 3000 Injections – FS (1 CME)</td>
<td>Diplomat Ballroom 3-5, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Frontiers in ED Addiction Care – FS (1 CME)</td>
<td>Regency Ballroom, Second Floor</td>
</tr>
<tr>
<td></td>
<td>Gaming Disorder 101: How to Distinguish Passion from Problem – FS (1 CME)</td>
<td>Grand Ballroom East, Second Floor</td>
</tr>
</tbody>
</table>
4:30 pm – 5:30 pm
Provider Bias In The Treatment Of Opioid Use Disorder – WS (1 CME)
The Role of Opioid Metabolic Pathways in Interpreting Urine Drug Testing Results – FS (1 CME)

8:00 pm – 9:00 pm
⭐️ Black Men in White Coats: From Awareness to Action – GS (1 CME)

9:00 pm – 10:00 pm
Mutual Help

Sunday, April 3, 2022

6:30 am – 7:30 am
Mutual Help

7:00 am – 8:00 am
Continental Breakfast
Ruth Fox Endowment Scholarship Recipients Meeting

8:00 am – 9:00 am
ASAM Registration & Education Desk Open
Changing the Focus: Envisioning Alcohol Use Through a Harm Reduction Lens – WS (1 CME)
Do AA and NA Work? If So, How Do They work? – WS (1 CME)
Facts About Fentanyl – FS (1 CME)
HIV Screening, Diagnosis, and Rapid Antiretroviral Therapy Start – FS (1 CME)
March of Dimes COMPASSION Supportive Group Model for Birthing People with SUD – WS (1 CME)

9:00 am – 9:30 am
Beach Break

9:30 am – 10:30 am
Cannabis Conversations – FS (1 CME)
Improving Patient Outcomes Through Fully Integrated Peer Recovery Support Services – FS (1 CME)
Loneliness, Loss and Love: How to Keep Going in 2022 – WS (1 CME)
Moving Beyond Naloxone: Integrating Harm Reduction Into Office-Based Addiction Treatment – FS (1 CME)
Stories of Our Ancestors: The impact of Culture, Race, Trauma on Addictions – WS (1 CME)

10:30 am – 11:00 am
Refreshment Break

11:00 am – 12:00 pm
A Telemedicine Bridge Clinic Successfully Engages Patients in Buprenorphine Treatment – FS (1 CME)
Considerations in Referring to Mutual Aid Groups: Legal, Ethical, Clinical & Pragmatic – FS (1 CME)
Strengthening Substance Use Prevention Messaging for Youth in the Wake of COVID-19 – WS (1 CME)
Toxicology Topics: Drug Levels for Buprenorphine: Efficacy, Diversion, and Compliance – WS (1 CME)

12:00 pm
Official Close of the ASAM 53rd Annual Conference! See you next year from April 13 - 16, 2023!

“This was the best conference I have attended in years. Thank you for the work you have done to put on such a high caliber event.”
OVERVIEW

The ASAM Fundamentals of Addiction Medicine is an innovative, case-based, interactive workshop for providers who are new to seeing patients at risk or treating patients with addiction. Participants receive an overview of the basics of addiction medicine, which covers how to screen, diagnose, treat, and/or refer patients with addiction, many of whom have co-occurring medical and psychiatric comorbidities.

At this live, energetic and interactive workshop, attendees will work through session activities and cases presented by faculty with participants at their table. Sessions throughout the day will include approximately equal parts lecture, demonstration of skills and skill building.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners should be able to:
1. Identify one’s own feelings and attitudes that promote or prevent therapeutic responses to patients with substance use disorders.
2. Apply the philosophy of harm reduction to enhance patient centered care for people with substance use disorders.
3. Demonstrate a knowledge of the neurobiological changes that occur during addiction.
4. Use motivational interviewing to enhance patient’s readiness to change unhealthy behaviors.
5. Use validated patient screening tools to detect substance use and interpret a spectrum of results.
6. Conduct substance use assessments using the DSM-5 criteria and including a biopsychosocial approach.
7. Offer evidence-based pharmacotherapy and behavioral interventions that are appropriate to specific substances and usage patterns.

SCHEDULE

7:00 am – 8:00 am
Breakfast

8:00 am – 9:00 am
Session 1: An Introduction to Addictive Disorders
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM
Brandon George

9:00 am – 9:45 am
Session 2: The Clinical Manifestations of the Neurobiology of Addiction
Lipi Roy, MD, MPH, FASAM

9:45 am – 10:15 am
Session 3: A Brief Overview of Motivational Interviewing Basics
Kathryn Basques, MSW, MSN, APN, PMHNP-BC
Amy Parins, DMSc, PA-C

10:15 am – 10:30 am
Refreshment Break

10:30 am – 11:25 am
[Continued] Session 3: A Brief Overview of Motivational Interviewing Basics
Kathryn Basques, MSW, MSN, APN, PMHNP-BC
Amy Parins, DMSc, PA-C

11:25 am – 12:00 pm
Session 4: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
J. Paul Seale, MD, FASAM

12:00 pm – 1:00 pm
Lunch

1:00 pm – 2:10 pm
[Continued] Session 4: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
J. Paul Seale, MD, FASAM

2:10 pm – 3:00 pm
Session 5: Identifying Unhealthy Substance Use: Assessment
Abby S. Letcher, MD, FASAM
Kathryn Basques, MSW, MSN, APN, PMHNP-BC
Brandon George

3:00 pm – 3:30 pm
Session 6: Treating Substance Use Disorders with Medication and Counseling
Kirk D. Moberg, MD, PhD, FACP, FACPE, CPE, DFASAM
Kathryn Basques, MSW, MSN, APN, PMHNP-BC

3:30 pm – 3:45 pm
Refreshment Break

3:45 pm – 5:20 pm
[Continued] Session 6: Treating Substance Use Disorders with Medication and Counseling
Kirk D. Moberg, MD, PhD, FACP, FACPE, CPE, DFASAM
Kathryn Basques, MSW, MSN, APN, PMHNP-BC

5:20 pm – 5:30 pm
Review and Workshop Wrap-Up
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM
FACULTY

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM

Kathryn M. Basques, MSW, MSN, APN, PMHNP-BC

Brandon George

Abby S. Letcher, MD, FASAM

Kirk D. Moberg, MD, PhD, FACP, FACPE, CPE, DFASAM

Amy Parins, DMSc, PA-C

Lipi Roy, MD, MPH, FASAM

J. Paul Seale, MD, FASAM

PROGRAM PLANNING COMMITTEE

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM, Chair

Abby S. Letcher, MD, FASAM, Vice Chair

Kathryn M. Basques, MSW, MSN, APN, PMHNP-BC

Angela L. Colistra, PhD, LPC, CAADC, CCS

Trina Fullard, MA, CCS, LCAS

Joanna Linn, PhD, LCMHCS, LCAS, CCS

Kirk D. Moberg, MD, PhD, FACP, FACPE, CPE, DFASAM

Amy Parins, DMSc, PA-C

Lipi Roy, MD, MPH, FASAM

J. Paul Seale, MD, FASAM

CONTINUING MEDICAL EDUCATION CREDIT & MOC

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit designation Statement

The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Family Physicians (AAFP)

The AAFP has reviewed The ASAM Fundamentals of Addiction Medicine Workshop, and deemed it acceptable for up to 8 In-Person, Live (could include online) AAFP Prescribed credit. Term of approval is from 02/17/2022 to 02/17/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Physician Assistants (AAPA)

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 2/17/2022 to 2/17/2023. AAPA reference number: CME-204325.

American Association of Nurse Practitioners (AANP)

This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 8 contact hours of accredited education.

More credit types available

Visit the ASAM Booth to Learn More!

Not a Member? Join during the Conference!

New members will be entered to win an Apple Watch!
OVERVIEW
The ASAM Motivational Interviewing Workshop is an interactive and engaging workshop that introduces and expands participants’ knowledge on utilizing Motivational Interviewing (MI) in an addiction treatment setting. MI is a goal-oriented, collaborative counseling style that evokes a person’s own motivations for and commitment to change.

Physicians, clinicians, counselors, and all those working with patients with addiction often find that one of the main barriers to effective treatment is the patients’ perceived lack of motivation to make changes. Without motivation on the patient’s part, making or sustaining progress with treatment goals can be difficult. MI is one technique that treatment providers can utilize to help patients make positive changes.

Participants of this workshop will be introduced to the key concepts and skills of MI and explore ways to effectively integrate MI into addiction treatment to help promote positive patient outcomes.

LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be able to:
1. Apply the spirit of MI to clinical practice.
2. Organize clinical communications attending to the four foundational processes of MI (engaging, focusing, evoking, and planning).
3. Compare and contrast MI congruent interactions with MI dissonant interactions.
4. Recognize, respond and evoke to change talk and understand sustain talk.
5. Apply the basic MI skills of open-ended questions, affirmations, reflective listening, and summaries to selectively reinforce change talk.
6. Identify further training opportunities for practicing the skills of MI.

I will keep on attending, wonderful to meet other providers doing the same thing as me.
Pre-Conference Offerings

CONTINUING MEDICAL EDUCATION CREDIT & MOC

ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Family Physicians (AAFP)
The AAFP has reviewed The ASAM Motivational Interviewing Workshop and deemed it acceptable for up to 8.00 In-Person, Live (could include online) AAFP Prescribed credits. Term of Approval is from 03/31/2022 to 03/31/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Physician Assistants (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 3/31/2022 to 3/31/2023. AAPA reference number: CME-204324.

American Association of Nurse Practitioners (AANP)
This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 8 contact hours of accredited education.

More credit types available

FACULTY
Brian Hurley, MD, MBA, DFASAM
Carla Marienfeld, MD, FAPA, FASAM

PROGRAM PLANNING COMMITTEE
Brian Hurley, MD, MBA, DFASAM, Chair
Carla Marienfeld, MD, FAPA, FASAM, Vice Chair
Jeffrey Devido, MD, MTS, FAPA, FASAM
Caridad Ponce-Martinez, MD

American Society of Addiction Medicine
Thanks Our Annual Conference Supporters

GOLD SPONSOR
Indivior

SILVER SPONSOR
Kipu Health
Landmark Recovery
Orexo
Pear Therapeutics

BRONZE SPONSOR
Alkermes
CARF International
Christopher D. Smithers Foundation
Heron Therapeutics
Total Brain

Special Thank You to the Florida Society of Addiction Medicine
OVERVIEW

Interdisciplinary care for patients with pain and addiction in the virtual age

The ASAM Pain & Addiction: Common Threads Course is one of ASAM’s longest running and most popular courses. This advanced course increases learners’ understanding of complex topics and improves treatment of patients who fall somewhere in the gray area around pain and addiction. Participants will learn new research developments that affect treatment, and how to integrate these techniques into their own practices. This year’s course will utilize a dynamic mix of teaching methods to engage an advanced audience.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners should be able to:

1. Describe new challenges in pain and addiction that have arisen from the COVID-19 pandemic.
2. Identify strategies to build resilience among healthcare teams and patients.
3. Differentiate between various interdisciplinary care models for treating patients with pain and addiction and explain the purpose of utilizing an interdisciplinary care team.
4. Describe common ways patients may be using Kratom as an alternative method for treatment of pain.
5. Compare different treatment options for patients who cannot tolerate buprenorphine.
6. Implement practical strategies and principles of a successful virtual pain and addiction assessment.
7. Question the disparities in access to telemedicine that exists within the US and recognize the current and future telemedicine policies that affect patients’ access to treatment.
8. Recognize the complex relationship between stimulants and chronic pain.
9. Assess the current fentanyl epidemic and discuss promising treatment and harm-reduction practices.
10. Compare key pain and addiction research publications from 2021-2022 and identify their relevance to practice.

SCHEDULE

7:00 am – 8:00 am
Breakfast

8:00 am – 8:15 am
Course Welcome & Introductions
William F. Haning III, MD, DLFAPA, DFASAM
William S. Jacobs, Jr, MD, FASAM

8:15 am – 9:15 am
New Challenges in Pain & Addiction Arising from the COVID-19 Pandemic
Barbara St. Marie, PhD, AGPCNP, FAANP, FAAN

9:15 am – 10:15 am
Building Resiliency & Fostering Wellness Among your Patients and Healthcare Team
Matt Herbert, PhD

10:15 am – 10:30 am
Refreshment Break

10:30 am – 11:30 am
Interdisciplinary Care for Pain & Addiction
Bethany DiPaula, PharmD, BCPP, FASHP
Eric Hanson, PhD
Anita Karnik, MD
Aram Mardian, MD
Daniel Vilaubi, DPT

11:30 am – 12:00 pm
Strategies for Conducting a Virtual Pain & Addiction Assessment with Interdisciplinary Care
Pam Pentin, MD

12:00 pm – 1:00pm
Lunch, Audience Question & Answer

1:00 pm – 1:30 pm
Addressing the Digital Divide: Disparities in Access to Telemedicine
Mollie B. Nisen, MD
Vania P. Rudolf, MD, MPH, DFASAM

1:30 pm – 2:00 pm
My Patient Can’t Tolerate Buprenorphine, Now What?
Michael Sprintz, DO, DFASAM

2:00 pm – 2:30 pm
Use of Kratom as an Alternative Pain Treatment
Stephanie T. Weiss, MD, PhD

2:30 pm – 3:00 pm
Stimulants: The Complex Relationship With Chronic Pain
Phillip Coffin, MD, MIA, FACP, FIDSA

3:00 pm – 3:30 pm
Annual Review of Pain & Addiction Medicine: Key Publications from 2021-2022 (Part 1)
Marianne Logan Fingerhood, DNP, ANP-BC, CNE
Laura M. Frankart, PharmD, MEd, BCPS
Emanuel N. Husu, MD

3:30 pm – 3:45 pm
Refreshment Break
Pre-Conference Offerings

3:45 pm – 4:15 pm
Annual Review of Pain & Addiction Medicine: Key Publications from 2021-2022 (Part 2)
Marianne Logan Fingerhood, DNP, ANP-BC, CNE
Laura M. Frankart, PharmD, MEd, BCPS
Emanuel N. Husu, MD

4:15 pm – 5:00 pm
Surfing the 3rd Wave: The Fentanyl Problem
Gregory Rudolf, MD, DFASAM

5:00 pm – 5:30 pm
Audience Question & Answer, Course Wrap-Up
William S. Jacobs, Jr, MD, FASAM

PROGRAM PLANNING COMMITTEE
William S. Jacobs, Jr, MD, FASAM, Chair
Gregory Rudolf, MD, DFASAM, Vice Chair
Harithsa S. Asuri, MD
Gregory X. Boehm, MD, DFASAM
Marianne L. Fingerhood, DNP, ANP-BC, CNE
Laura M. Frankart, PharmD, MEd, BCPS
Emanuel N. Husu, MD
Karishma Jagtani, PA-C
Denise M. Josey, MD, MPH, MS
Aram Mardian, MD
Launette M. Rieb, MD, MSc, CCFP, FCFP, FASAM

CONTINUING MEDICAL EDUCATION CREDIT & MOC
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Family Physicians (AAFP)
The AAFP has reviewed The ASAM Pain & Addiction: Common Threads Course XXIII and deemed it acceptable for up to 8.00 Live AAFP Prescribed credits. Term of Approval is from 03/31/2022 to 03/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Academy of Physician Assistants (AAPA)
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 3/31/2022 to 3/31/2023. AAPA reference number: CME-204636.

American Association of Nurse Practitioners (AANP)
This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 8 contact hours of accredited education.

More credit types available

www.TheASAMAnnualConference.org

Addiction Medicine Certification Exams

American Board of Preventive Medicine
Application Period: March - June 2022
Exam Administration: October 2022
Learn More: www.TheABPM.org/am-i-eligible

American Osteopathic Association
Application Period: June - October 2022
Exam Administration: November 2022
Learn More: https://certification.osteopathic.org/addiction-medicine/

Get Exam Ready with ASAM: https://elearning.asam.org/examprep
The full conference schedule (including speaker information, presentation slides, and more) is available on the conference website (https://bit.ly/ASAM2022Schedule) and in the ASAM Events app.

**PRE-CONFERENCE ACTIVITIES**

**TUESDAY, MARCH 29, 2022**

6:00 pm – 9:00 pm  
Board of Directors Meeting  
33rd Floor Lounge, 33rd Floor

**WEDNESDAY, MARCH 30, 2022**

8:30 am – 5:00 pm  
Board of Directors Meeting  
33rd Floor Lounge, 33rd Floor

5:00 pm – 6:00 pm  
Fundamentals Workshop Faculty Meeting  
317 Conference Room, Third Floor

**THURSDAY, MARCH 31, 2022**

6:30 am – 7:30 am  
Mutual Help  
302 Conference Room, Third Floor

7:00 am – 8:00 am  
Pre-Conference Course/Workshop Continental Breakfast  
Pre-Conference Course/Workshop Rooms, Second Floor

**SESSIONS KEY**

<table>
<thead>
<tr>
<th>TITLE</th>
<th>INTRODUCTORY</th>
<th>INTERMEDIATE</th>
<th>ADVANCED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
<tr>
<td>Medical Knowledge</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
<tr>
<td>Practice-Based Improvement</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
<tr>
<td>Interpersonal Skills</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
<tr>
<td>Professionalism</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
<tr>
<td>Systems Based Practice</td>
<td>![icon]</td>
<td>![icon]</td>
<td>![icon]</td>
</tr>
</tbody>
</table>

8:00 am – 5:30 pm  
**Pre-Conference Workshop – 8 CME**  
**ASAM Fundamentals of Addiction Medicine Workshop**  
Regency Ballroom, Second Floor  
See page 12-13 for more information.

8:00 am – 5:30 pm  
**Pre-Conference Workshop – 8 CME**  
**ASAM Motivational Interviewing Workshop**  
Atlantic Ballroom 2&3, Second Floor  
See page 14-15 for more information.

3:00 pm – 7:00 pm  
**ASAM Booth Open**  
Great Hall Foyer, Third Floor

**ANNUAL CONFERENCE BEGINS**

5:30 pm – 6:30 pm  
**New Member & First Time Attendee Welcome Reception**  
Great Hall Foyer 6, Third Floor

5:30 pm – 7:30 pm  
**Exhibit Hall Open**  
Great Hall 1-3, Third Floor

6:30 pm – 8:00 pm  
**President’s Ruth Fox Reception for Awardees and Donors**  
(By Invitation Only)  
33rd Floor Lounge, 33rd Floor

7:30 pm – 8:30 pm  
**Collaborative Session – 1 CME**  
**Becoming Certified in Addiction Medicine and How to Continue That Certification**  
Grand Ballroom West, Second Floor  
Michael F. Weaver, MD, DFASAM; Christopher J. Ondrula, JD  
Developed in Cooperation with the American Board of Preventive Medicine (ABPM)  
Physicians who are or have previously been certified by a Member Board of the American Board of Medical Specialties can now become certified in the subspecialty of Addiction Medicine by the American Board of Preventive Medicine (ABPM). This session will review the requirements and various pathways available for physicians to apply to sit for the Addiction Medicine subspecialty exam. Information will be provided for attendees who are already certified in Addiction Medicine by ABPM about updates to the maintenance of certification (MOC) platform and the ABPM’s transition to an innovative and flexible Continuing Certification Program (CCP).
FRIDAY, APRIL 1, 2022

6:30 am – 7:30 am

Mutual Help
302 Conference Room, Third Floor

Mutual Help
 Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.

7:00 am – 8:00 am

Medical Toxicology Special Interest Group Meeting
Atlantic Ballroom 1, Second Floor

Opioid Treatment Program Special Interest Group Meeting
Diplomat Ballroom 1-2, Second Floor

Physicians Health Special Interest Group Meeting
Diplomat Ballroom 3-5, Second Floor

Ruth Fox Endowment Scholarship Recipients Meeting
303 Conference Room, Third Floor

Stretch Out the Stress! Morning Yoga
South Palm Court, First Floor

8:00 am – 5:00 pm

ASAM Booth Open
Great Hall Foyer, Third Floor

8:30 am – 10:00 am

General Session – 1.5 CME
Opening Scientific Plenary & Distinguished Scientist Lecture
Great Hall 4-6, Third Floor
Shari M. Ling, MD; Chinazo O. Cunningham, MD, MS; Peter Bruun, MFA; William F. Haning III, MD, DLFAPA, DFASAM
See page 20 for more information.

10:00 am – 10:30 am

Refreshment Break
Great Hall 1-3, Third Floor

10:00 am – 10:30 am

Speaker Meet & Greet
ASAM Booth, Great Hall Foyer, Third Floor

10:00 am – 5:00 pm

Exhibit Hall Open
Great Hall 1-3, Third Floor

10:30 am – 11:30 am

Collaborative Session – 1 CME
Advances in Treatments for Methamphetamine Use Disorder
Regency Ballroom, Second Floor
Madhukar H. Trivedi, MD; Kathleen T. Brady, MD, PhD; Manish K. Jha, MBBS
Developed in Cooperation with the National Institute on Drug Abuse (NIDA)
Although treatment admissions for methamphetamine use disorder (MUD) have risen, there are few effective treatments and no FDA approved medication to date. In this session, the presenters will provide research updates on treatments for MUD focusing on pharmacotherapy, brain stimulation, including transcranial stimulation (TMS), and Ketamine. Each presenter will provide a draft outline for respective planned clinical trials to be conducted in NIDA’s National Drug Abuse Treatment Clinical Trials Network (CTN). The session will conclude with a chair-moderated panel discussion and audience question and answer segment.

11:30 am – 12:30 pm

ASAM Registration & Education Desk Open
Great Hall Foyer, Third Floor

12:30 pm – 1:30 pm

Luncheon
Great Hall 1-3, Third Floor

1:30 pm – 5:00 pm

Exhibit Hall Open
Great Hall 1-3, Third Floor

7:30 pm – 8:30 pm

Collaborative Session – 1 CME
Developing Addiction Medicine Fellowships
Regency Ballroom, Second Floor
Andrew A. Danzo; Jeanette M. Tetrauld, MD, FACP, DFASAM; Timothy K. Brennan, MD, MPH
Developed in Cooperation with the American College of Academic Addiction Medicine (ACAAM)
This session offers an in-depth review of addiction medicine fellowship programs and practical information for those who are interested in developing a new program or pursuing fellowship training. Topics addressed will include recent developments, such as the introduction of virtual meetings, didactics, and related activities to help promote collaboration and group learning in the growing academic addiction medicine community. For providers who are interested in pursuing fellowship training, the presenters will offer an inside view of the type of clinical experiences and educational activities that can be expected.

Collaborative Session – 1 CME
Navigating the Osteopathic Addiction Medicine Certification Exam
Atlantic Ballroom 2&3, Second Floor
Marla Kushner, DO, FSAMH, FACOFP, DFASAM; Anthony H. Dekker, DO, FAOAAM, DFASAM; Nina A. Vidmer
Developed in Cooperation with the American Osteopathic Academy of Addiction Medicine (AOAAM)
The presentation will focus on the certification exam as administered by the American Osteopathic Conjoint Examination Committee on Addiction Medicine and the subspecialty certification exams and osteopathic continuous certification (recertification) examinations. The panel will discuss the application process and best practices on sitting for the exam. Presenters will answer questions from audience members interested in this opportunity for certification.

Child & Adolescent Addiction Special Interest Group Meeting
Atlantic Ballroom 1, Second Floor

Criminal Justice Special Interest Group Meeting
Diplomat Ballroom 3-5, Second Floor

Nicotine & Tobacco Issues Special Interest Group Meeting
Diplomat Ballroom 1&2, Second Floor

Women & SUDs Special Interest Group Meeting
Grand Ballroom East, Second Floor

8:00 pm – 10:00 pm

Chapter Leadership & Policy Roundtable Meeting
303 Conference Room, Third Floor

9:00 pm – 10:00 pm

Mutual Help
302 Conference Room, Third Floor

Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.

7:00 am – 8:00 am

Medical Toxicology Special Interest Group Meeting
Atlantic Ballroom 1, Second Floor

Opioid Treatment Program Special Interest Group Meeting
Diplomat Ballroom 1&2, Second Floor

Physicians Health Special Interest Group Meeting
Diplomat Ballroom 3-5, Second Floor

Ruth Fox Endowment Scholarship Recipients Meeting
303 Conference Room, Third Floor

Stretch Out the Stress! Morning Yoga
South Palm Court, First Floor

Breathe in, breathe out. Join your colleagues for a morning of downward-facing dogs and warrior poses. All levels welcome and mats are provided.

7:00 am – 6:00 pm

ASAM Registration & Education Desk Open
Grand Ballroom Foyer, Second Floor

7:30 am – 8:30 am

Continental Breakfast
Great Hall Foyer, Third Floor

8:00 am – 5:00 pm

ASAM Booth Open
Great Hall Foyer, Third Floor

8:30 am – 10:00 am

General Session – 1.5 CME
Opening Scientific Plenary & Distinguished Scientist Lecture
Great Hall 4-6, Third Floor
Shari M. Ling, MD; Chinazo O. Cunningham, MD, MS; Peter Bruun, MFA; William F. Haning III, MD, DLFAPA, DFASAM
See page 20 for more information.

10:00 am – 10:30 am

Refreshment Break
Great Hall 1-3, Third Floor

10:00 am – 10:30 am

Speaker Meet & Greet
ASAM Booth, Great Hall Foyer, Third Floor

10:00 am – 5:00 pm

Exhibit Hall Open
Great Hall 1-3, Third Floor

10:30 am – 11:30 am

Collaborative Session – 1 CME
Advances in Treatments for Methamphetamine Use Disorder
Regency Ballroom, Second Floor
Madhukar H. Trivedi, MD; Kathleen T. Brady, MD, PhD; Manish K. Jha, MBBS
Developed in Cooperation with the National Institute on Drug Abuse (NIDA)
Although treatment admissions for methamphetamine use disorder (MUD) have risen, there are few effective treatments and no FDA approved medication to date. In this session, the presenters will provide research updates on treatments for MUD focusing on pharmacotherapy, brain stimulation, including transcranial stimulation (TMS), and Ketamine. Each presenter will provide a draft outline for respective planned clinical trials to be conducted in NIDA’s National Drug Abuse Treatment Clinical Trials Network (CTN). The session will conclude with a chair-moderated panel discussion and audience question and answer segment.
OPENING SCIENTIFIC PLENARY SESSION

Friday, April 1, 2022  |  8:30 am - 10:00 am  |  Great Hall 4-6, Third Floor

The ASAM 53rd Annual Conference begins with the Opening Scientific Plenary Session. This session, moderated by ASAM President, Dr. William F. Haning III, brings together renowned names in the addiction medicine field to motivate and energize conference attendees.

**SCHEDULE**

8:30 am – 8:40 am  Welcome to ASAM 53rd Annual Conference & the Opening Scientific Plenary
William F. Haning III, MD, DLFAPA, DFASAM

8:40 am – 9:05 am  CMS’ Actions to Address the Overdose Crisis
Shari M. Ling, MD
Dr. Shari Ling, Deputy Chief Medical Officer at the Centers for Medicare & Medicaid Services, will provide an overview of CMS actions to address the overdose crisis. She will discuss existing and evolving CMS programs and policies under Medicare, Medicaid, and the Marketplace to support behavioral health. Dr. Ling will share information on coverage and payment for mental health services, treatment for beneficiaries with substance use disorders, telehealth flexibilities, and resources to help the people that you serve.

9:05 am – 9:30 am  Improving Access to Care and Health Outcomes Among People Who Use Drugs: Lessons Learned by Thinking Out of the Box
Chinazo O. Cunningham, MD, MS, FASAM
As a physician who has spent 20 years treating opioid addiction in the Bronx, Dr. Chinazo Cunningham has witnessed how innovation can improve access to care and ultimately improve the health outcomes of people who use drugs. This session, featuring the R. Brinkley Smithers Distinguished Scientist Award winner, will explore the future of the rapidly changing field of addiction medicine and lessons learned from “out of the box” approaches.

9:30 am – 9:55 am  Pebbles in a Pond
Peter Bruun, MFA
The death of a loved one from an overdose can have a devastating effect on a family and community. Through his artwork and powerful personal story, Peter Bruun, a renowned artist, educator, and curator, will discuss how caring providers can make a difference. The work of addiction professionals is like tossing a pebble in a pond: a seemingly small thing, but in fact, it sends out ripple after ripple; little widening waves washing over many.

9:55 am - 10:00 am  Closing Remarks & Adjourn
William F. Haning III, MD, DLFAPA, DFASAM

**SESSION MODERATOR**

William F. Haning III, MD, DLFAPA, DFASAM
President
American Society of Addiction Medicine
Focus Session – 1 CME
Buprenorphine Dose Limits - What Is The Evidence?
Grand Ballroom East, Second Floor
MaryAnne C. Murray, DNP, EdD, PMHNP-BC, FNP-BC, CARN-AP; Lucinda A. Grande, MD; Tricia E. Wright, MD, MS, FACOG, DFASAM; Dave Cundiff, MD, MPH
This session provides a review of evidence for the initial recommendations of dosing limits for buprenorphine and the safety and advisability of higher doses in select patients given the current overdose crisis of synthetic opioids, such as fentanyl. Additionally, this session examines the needs of special populations, such as patients with co-existing pain, poly-substance use, pregnant patients, and diversion.

Focus Session – 1 CME
Cannabis Use in Pregnancy: Person-Centered Perspectives
Atlantic Ballroom 2&3, Second Floor
Katrina Mark, MD; Mishka Terplan, MD, MPH, FACOG, DFASAM; David Schiff, MD, MSc
This session will discuss cannabis use in pregnancy, lactation, and early parenting in the setting of increasing prenatal use despite professional guidance discouraging the use of cannabis in pregnancy. Specific attention will be paid to medical versus non-medical cannabis use in the preconception, post conception, and postpartum periods. The purpose of this session is to discuss cannabis use in pregnancy in an up-to-date way from a person-centered perspective and to address challenges in identifying cannabis use versus use disorder in the perinatal period.

Focus Session – 1 CME
How We Built This: Improving Treatment Access and Engagement for Hispanic/Latinx Patients
Diplomat Ballroom 3-5, Second Floor
Heather Ihrig, RN, MSN, MBA; Lesley Brooks, MD; Hans J. Pearson; Meredith N. Silverstein, PhD
Many Hispanic/Latinx patients do not receive needed Substance Use Disorder (SUD) treatment, and, in cases where treatment is available, there are often lower treatment completion rates for Hispanic/Latinx patients as compared with non-Hispanic white patients. The Colorado Opioid Synergy Larimer and Weld (COSLAW) project, a network of SUD treatment providers and a team of integrated care coordinators, was created to increase patient access to treatment while reducing racial and ethnic health disparities. This session provides an overview of the COSLAW model, lessons learned about improving equity in engagement, strategies for engaging Hispanic/Latinx people with SUD services, and approaches for working with providers to enhance culturally relevant treatment services and approaches.

Focus Session – 1 CME
Medication in Opioid Courts: Reducing Overdose Through Triage in Court Settings
Diplomat Ballroom 1&2, Second Floor
Kimberly A. Schwarz, MS; Jo Ann Ferdinand, Esq; Charles W. Morgan, MD, FAAFP, DFASAM; Dennis A. Reilly, Esq
Opioid treatment courts offer immediate access to medication, as well as intense supervision and support to people with criminal justice involvement. This session focuses on how to promptly identify opioid use disorder, provide access to services, prescribe medications for treatment of opioid use disorder (MOUD), and engage people in specialty care treatment by sharing lessons from court practitioners and their partners, including recovery support services and peer advocates. While opioid treatment courts save lives, they have also faced barriers. Recent innovations were developed during the COVID-19 pandemic that could make it easier to connect patients to MOUD. These innovations are explored in this session, including how to engage practitioners who prescribe MOUD.
BIG IDEAS PLENARY SESSION
Friday, April 1, 2022    |    1:00 pm – 2:30 pm    |    Great Hall 4-6, Third Floor

Operationalizing Racial Justice and Equity in Healthcare

What big ideas are shaping the future of Addiction Medicine? Draw inspiration from ASAM award recipients and insights from national innovators during the Big Ideas Plenary Session! ASAM President, Dr. William F. Haning III, will recognize award recipients who are making major contributions to the field. Annual Conference Planning Committee Chair, Dr. Anika A.H. Alvanzo, will moderate a lively session with time for Q&A on Operationalizing Racial Justice and Equity in Healthcare.

Karthik Sivashanker, MD, MPH, CPPS
Vice President of Equitable Health Systems and Innovation, AMA

Ayana Jordan, MD, PhD
Associate Professor of Psychiatry
NYU Grossman School of Medicine

SESSION MODERATOR
Anika A. H. Alvanzo,
MD, MS, FACP, DFASAM
Annual Conference Planning Committee Chair
American Society of Addiction Medicine

AWARDS MODERATOR
William F. Haning III, MD,
DLFAPA, DFASAM
President
American Society of Addiction Medicine

SCHEDULE
1:00 pm – 1:05 pm Welcome to the Big Ideas Plenary
William F. Haning III, MD, DLFAPA, DFASAM

1:05 pm – 1:30 pm Acknowledgement of Award Recipients
ASAM Media Award – Dale Okorodudu, MD
ASAM Annual Award – Timothy Wiegand, MD, FACMT, FAACT, DFASAM
ASAM Educator of the Year Award – David Mee-Lee, MD, DFASAM
John P. McGovern Award – Kelly J. Clark, MD, MBA, DLFAPA, DFASAM

1:30 pm – 1:35 pm Introduction of Presentations
Anika A. H. Alvanzo, MD, MS, FACP, DFASAM

1:35 pm – 1:50 pm Operationalizing Racial Justice and Equity in Healthcare
Karthik Sivashanker, MD, MPH, CPPS
This interactive presentation will cover foundational concepts on health equity, including the various types of bias and discrimination commonly seen in healthcare. Dr. Sivashanker will also present a new framework for advancing racial justice and equity in the healthcare arena by leveraging high-performance quality and safety practices to systematically make inequities visible and to address and resolve them as an integral part of healthcare practice. Learners will be able to identify specific strategies for effectively leveraging existing quality/safety infrastructure and processes to advance equity.

1:50 pm - 2:05 pm Imani Breakthrough: An Innovative Recovery Program for Black and Latinx People Who Use Opioids and Other Substances
Ayana Jordan, MD, PhD
This presentation focuses on upstream causes and enduring consequences of health disparities and racial oppression in addiction. COVID-19 has sharply outlined the urgent need to dismantle these systems, mitigate behaviors, and improve health outcomes of racial and ethnic minoritized people with substance use disorders (SUDs). We will discuss culturally relevant research techniques and clinical interventions that employ an anti-racist framework to model how health equity in addiction medicine can be achieved.

2:05 pm - 2:25 pm Panel Discussion
Karthik Sivashanker, MD, MPH, CPPS
Ayana Jordan, MD, PhD
Anika A. H. Alvanzo, MD, MS, FACP, DFASAM

2:25 pm – 2:30 pm Closing Remarks
Anika A. H. Alvanzo, MD, MS, FACP, DFASAM
3:00 pm – 4:00 pm

Workshop Session – 1 CME
Addiction Medicine in Healthcare Education - Listening to Students and Facilitating Faculty
Atlantic Ballroom 2&3, Second Floor
Stephen A. Wyatt, DO; Jenifer Van Deusen, MEd; Cara A. Poland, MD, MEd; Nivetha Saravanan

There is growing evidence that medical school education should include a stronger foundation in the skills and knowledge of the principles of addiction medicine. This opens the door for specialists in addiction medicine and psychiatry to take a greater role in student education. This session explores innovative strategies to enhance medical student understanding of substance use problems and addiction in all areas of healthcare.

Workshop Session – 1 CME
How to Implement Low-Dose Buprenorphine Initiation in Your Practice: A Case-Based Workshop
Regency Ballroom, Second Floor
Melissa B. Weimer, DO, MCR, FASAM; Shawn M. Cohen, MD; Kenneth L. Morford, MD

This session provides an in-depth review of the current evidence base for low dose initiation strategies and the various low-dose initiation strategies that are in use across the United States. This didactic presentation will review a newly-developed, shared decision tool that prescribers can use with their patients. At the end of the session, participants will be able to define current evidence for low dose buprenorphine initiation with patients.

Focus Session – 1 CME
Meeting People Where They Are: Corrections, Telehealth, and OUD
Grand Ballroom East, Second Floor
Allyson L. Smith, MD, FASAM; Jeremy A. Hubbard; Justin Schumacher, NCPRSS, PRC; Stephen A. Martin, MD, EdM, FAAFP, FASAM

Opioid use disorder does not disappear during incarceration and is not cured upon re-entry. Instead, people face profound hazards inside the walls and after release. Telehealth allows for scaled, effective, medication-based treatment during and after incarceration—especially with regulatory easing that began with the COVID-19 pandemic and is planned to be made permanent. The model presenters will discuss is designed to be readily replicated among a variety of types of correctional settings in different geographies by distinct clinical organizations. Participants in this session will review approaches to partnering and deploying the model, examine areas that may need troubleshooting, and obtain their own detailed description of workflow so as to best facilitate replication.

Focus Session – 1 CME
Naloxone: What You Need to Know
Great Hall 4-6, Third Floor
Evans Schwartz, MD, FASAM; Lewis S. Nelson, MD; JoAn Laes, MD; Robert C. Pueinger, MD

According to the CDC, the number of opioid overdoses has accelerated in the past year. This session examines naloxone use in emergency situations and cases where naloxone may not reverse opioid overdose. Additionally, this session explores cases where a partial agonist may be used with naloxone or as a substitute for naloxone. After this session, participants will be able to describe the use of buprenorphine after naloxone-pprecipitated withdrawal and whether or not the naloxone component of sublingual buprenorphine matters in these situations.

Collaborative Session – 1 CME
The Next Chapter: A Discussion on the Next Edition of The ASAM Criteria
Diplomat Ballroom 3-5, Second Floor
R. Corey Waller, MD, MS, FACEP, DFMASAM; Whitney L. Menarcheck, LPC, NCC; Sandra Gomez-Luna, MD, FASAM; Kimberley Johnson, PhD

This interactive session provides an opportunity for attendees to engage with the Editor-in-Chief and Editorial Team of The ASAM Criteria 4th Edition. The mission of the Editorial Team is to map the dimensional analysis and level of care decision rules to the latest evidence and methodologically derived expert opinion. The development of the 4th Edition will take into consideration a wide range of expertise and will rely heavily on feedback from the field. This panel will focus on getting feedback and suggestions from the audience that will help the Editorial Team and the writing groups to make the next edition of The ASAM Criteria as accurate, relevant, and helpful as possible for the field of addiction treatment.

Workshop Session – 1 CME
Virtual is Now Reality: Telehealth to Deliver Care for Substance Use Disorders
Grand Ballroom West, Second Floor
Brian M. Merrill, MD, MBA; Danielle Gainer, MD; Brent Schnipke, MD

This session provides an exploration of the context and considerations for using telehealth for the treatment of substance use disorders (SUD) and regulatory changes that have impacted care during the COVID-19 pandemic. In this session, outcome data and clinical cases that highlight the complexities of treating SUD with telehealth will be reviewed. This interactive session will include audience polling, brief small-group discussions, and question-answer.

4:00 pm – 4:45 pm

ASAM Fellows (FASAM) Meet-Up
ASAM Booth, Great Hall Foyer, Third Floor

4:00 pm – 5:00 pm

Ice Cream Social
Great Hall 1-3, Third Floor
Chat with colleagues and exhibitors over a delicious ice cream treat.

5:00 pm – 6:00 pm

Workshop Session – 1 CME
An Organizational Framework for Approaching Patients with OUD and Painful Serious Illness
Grand Hall 4-6, Third Floor
Janet J. Ho, MD, MPH; Katrina S. Nickels, MD; Julie Childers, MD, FASAM

Palliative care specialists are trained in pain management in the context of serious illnesses. However, they often lack training in primary addiction skills and will consult addiction specialists for guidance about opioid management. Unfortunately, the literature on pain in patients with serious illness and opioid use disorder is limited. This session will provide a framework to guide medical decision-making in the treatment of patients with opioid use disorder and painful serious illness. By having tools to help organize the total risks and benefits of opioids as analgesia and/or MOUD, addiction clinicians will be better prepared to provide peer training in primary addiction medicine skills and advise colleagues on comprehensive approaches to these challenging cases.
trends in alcohol use will be discussed. Intervention and how these short-term trends fit into longer-term decreases, among younger adults. The implications for prevention and differential effects by gender. There will be an examination of the pandemic has on alcohol use and alcohol use disorders, focusing on
This session provides an in-depth review of the impact the COVID-19 pandemic has on alcohol use and alcohol use disorders, focusing on unprecedented challenges to birthing people with substance use disorders, their families, and the providers caring for them. This sessions provides a review of evidence and strategies to help providers navigate these challenging times, including public-health research updates for treating pregnant persons with OUD, strategies to initiate buprenorphine, and methadone in pregnant persons using fentanyl, and adequate dosing of methadone during pregnancy using plasma levels and flexible dosing schedules.

Focus Session – 1 CME
History of the Stigma & Criminalization of OUD and it’s Treatment
Atlantic Ballroom 2&3, Second Floor
Melody J. Glenn, MD, MFA
This presentation traces the history of stigma within the field of addiction medicine and national drug policy from an anti-racist and harm-reduction lens from late 19th century to present day. A review of historical and emotional origins of stigma will provide insights into stigma’s many forms, the contributing factors of stigma, and impacts stigma has on addiction medicine from individual interactions with patients to national drug policy. This review of stigma’s role in addiction medicine includes the United States’ first drug legislation, the 1914 Harrison Act, the Lexington Narcotic Farm, the rise and fall of methadone maintenance, the democratization of naloxone, the origins of harm reduction, and the activists role behind syringe distribution. Participants of this session will gain anti-racist and historical perspectives to inform program and policy revisions.

Workshop Session – 1 CME
Supporting Birthing People and Families During COVID; Tools for Buprenorphine and Methadone
Grand Ballroom West, Second Floor
Vania P. Rudolf, MD, MPH, DFASAM; Ngoc H. Pham, MD; Tricia E. Wright, MD, MS, FACOG, DFASAM; Hendree E. Jones, PhD
The twin crises of COVID-19 and opioid overdose mortality pose unprecedented challenges to birthing people with substance use disorders, their families, and the providers caring for them. This sessions provides a review of evidence and strategies to help providers navigate these challenging times, including public-health research updates for treating pregnant persons with OUD, strategies to initiate buprenorphine, and methadone in pregnant persons using fentanyl, and adequate dosing of methadone during pregnancy using plasma levels and flexible dosing schedules.

Collaborative Session – 1 CME
The Impact of COVID on Alcohol Use Disorder: Epidemiology and Treatment
Grand Ballroom East, Second Floor
Katherine Keyes, PhD; Sherry McKee, PhD
Developed in Cooperation with the National Institute on Alcohol Abuse and Alcolholism (NIAAA)
This session provides an in-depth review of the impact the COVID-19 pandemic has on alcohol use and alcohol use disorders, focusing on differential effects by gender. There will be an examination of the evidence that alcohol consumption has increased for women in the mid-life during the COVID pandemic, and to a lesser degree, and even decreases, among younger adults. The implications for prevention and intervention and how these short-term trends fit into longer-term trends in alcohol use will be discussed.

Focus Session – 1 CME
Treat Addiction, Save Lives: The History of the American Society of Addiction Medicine
Diplomat Ballroom 3-5, Second Floor
David E. Smith, MD, FACT, DFASAM; Andrea G. Barthwell, MD, DFASAM; William F. Haring III, MD, DLFAPA, DFASAM
This session discusses a new ASAM publication, Treat Addiction. Save Lives: A History of the American Society of Addiction Medicine. Presenters will share the most interesting, entertaining, or surprising bit of history they learned through this project. Excerpts from the book will be recited to spark commentary and questions.

Workshop Session – 1 CME
Widening the Net: Engaging Sexual and Gender Minority Youth in Addiction Treatment
Diplomat Ballroom 1&2, Second Floor
Paula Goldman, MD; Megana Dwarkanath, MD, MEd; Stephanie P. Klipp, RN, CARN, CAAP, CRS; J. Deanna Wilson, MD, MPH
Sexual and gender minority (SGM) youth are at increased risk of substance use and misuse compared to their heterosexual and cisgender peers. The purpose of this session is to explore best practices for providing substance use care that is affirming and sensitive to the needs of SGM youth. Additionally, this session offers a review of the interrelation between substance use and high risk sexual behavior in youth. Participants will come away from this session with greater comfort engaging SGM youth in substance use treatment, integrating substance use treatment and gender- affirming care, and implementing harm reduction strategies specific to the needs of SGM youth, including STI screening, initiation and monitoring of PrEP, and office-based counseling.

6:00 pm – 7:30 pm
Happenin’ Havana Nights Party
Diplomat Landing, Across the Skybridge
Grab your fedora, put on festive party clothes, and join us by the scenic inter-coastal waterway! You’ll be treated to South Florida’s famous Cuban food specialties and an amazing sunset. Feel the rhythm of the Danzón music while you party and have fun with colleagues and friends. No passport needed!

7:30 pm – 8:30 pm
Addiction Consult Special Interest Group Meeting
Diplomat Ballroom 3-5, Second Floor

7:30 pm – 8:30 pm
Annual Conference Program Planning Committee Meeting
319 Conference Room, Third Floor

Journal of Addiction Medicine Editorial Meeting
316 Conference Room, Third Floor

Primary Care & Family Medicine Special Interest Group Meeting
Diplomat Ballroom 1&2, Second Floor

Twelve Step Recovery Special Interest Group Meeting
Atlantic Ballroom 1, Second Floor

9:00 pm – 10:00 pm
Mutual Help
302 Conference Room, Third Floor
Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.
SATURDAY, APRIL 2, 2022

6:30 am – 7:30 am
Mutual Help
302 Conference Room, Third Floor
Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.

7:00 am – 8:30 am
Continental Breakfast
Great Hall Foyer, Third Floor

7:00 am – 5:30 pm
ASAM Registration & Education Desk Open
Grand Ballroom Foyer, Second Floor

7:45 am – 8:15 am
ASAM: State of the Organization
Great Hall 4-6, Third Floor

8:00 am – 5:00 pm
ASAM Booth Open
Great Hall Foyer, Third Floor

8:30 am – 10:00 am
General Session – 1.5 CME
Policy & Science Plenary Session - Expanding Access to Care Through Telehealth: Lessons Learned During the Pandemic
Great Hall 4-6, Third Floor
Nângo A. Harrison, MD, FASAM; Brian Hurley, MD, MBA, DFASAM; Jake Ketchum III; Tyler Oesterle, MD, MPH; Vania P. Rudolf, MD, MPH, DFASAM; Rachel S. Weightman, MD
See page 26 for more information.

10:00 am – 11:30 am
Exhibit Hall Open
Great Hall 1-3, Third Floor

Refreshment Break
Great Hall 1-3, Third Floor

Poster Session – 1.5 CME
Scientific Poster Session 2
Great Hall Foyers, Third Floor
See page 38 for more information.

10:15 am – 11:15 am
Public Policy Committee Meeting
316 Conference Room, Third Floor

11:30 am – 12:30 pm
Workshop Session – 1 CME
Beyond the Lecture: Leading and Engaging Learners in Addiction Medicine Education
Diplomat Ballroom L&2, Second Floor
Michael Fingerhood, MD, FACP, DFASAM; Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM
Adults learn by listening, seeing and doing. However, for deep learning to occur, adults also need to learn by feeling and reflection. This interactive session will be a “play within a play” where participants will observe and practice ways to make their presentations more engaging and interactive to promote deeper learning amongst their audience. Special focus on small and large group case-based learning and the use of audience engagement with the management of audience dynamics will be reviewed.

Collaborative Session – 1 CME
Bridging the Gap Between Science and Clinical Practice in Addiction Medicine
Diplomat Ballroom 3-5, Second Floor
Sebastian T. Tong, MD, MPH, FASAM; Wilson M. Compton, MD, MPE; George F. Koob, PhD; Geetha A. Subramaniam, MD, DFAPA, DFAACAP; Elisabeth Kato, MD, MRP
Developed in Cooperation with the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ)
This session will provide an opportunity for bidirectional communication between federal science funding agencies and clinicians/clinician-researchers about “hot” topics in addiction medicine research and how to address the divide between research and clinical practice. Funding agency representatives will solicit clinicians’ feedback on which areas of research should be prioritized to improve clinical practice. Clinicians/clinician-researchers will learn about opportunities for increasing their participation in research. Participants also will engage in brainstorming about how to include more clinical voices in the shaping of addiction research priorities.

Focus Session – 1 CME
Cannabis: Products, Health Impact, Policies and Intervention
Grand Ballroom East, Second Floor
Victoria I. Pham, DO, MBA, FAPA, DFAACAP; Brian Hurley, MD, MBA, DFASAM
This session is designed to prepare clinicians to provide addiction medical management in patients who use cannabis. Patients who come to the attention of addiction physicians are increasingly likely to use cannabis. Increases in THC exposure elevates the risk of cannabis use disorder and the development of mental health conditions including cognitive problems. A firm understanding of the association between cannabis use, addiction to cannabis and/or other substances, and psychiatric symptoms and conditions is critical to the modern practice of addiction medicine. By the conclusion of the workshop, participants will have a stronger understanding of the importance of addressing cannabis use, addiction and treatment in patients who present for the treatment of addictive diseases.

Focus Session – 1 CME
Clinical Characterization of Kratom: Is it a Craze or Here to Stay?
Regency Ballroom, Second Floor
Stephanie T. Weiss, MD, PhD; Kirsten E. Smith, PhD, MSW
This session will provide a comprehensive, bench-to-bedside understanding of the psychoactive plant, kratom (Mitragyna speciosa), which is increasingly used in the United States to self-treat pain, psychiatric, and substance use disorder (SUD) symptoms. In this session, assessment, diagnosis, and intervention as they relate to SUD for kratom and kratom polydrug use will be discussed. Though limited, the most up-to-date animal and human research on kratom will be presented. Best practices for clinicians who are likely to encounter kratom-using patients will be provided along with suggestions for future research.
POLICY & SCIENCE PLENARY SESSION
Saturday, April 2, 2022   |   8:30 am – 10:00 am   |   Great Hall 4-6, Third Floor

Expanding Access to Care through Telehealth: Lessons Learned During the Pandemic

While there has long been interest in expanding access to addiction treatment through telehealth, there have historically been both regulatory and financial barriers that limited adoption. Through the COVID-19 public health emergency, federal and state regulations governing telehealth have been relaxed and payment mechanisms have expanded, leading to broad adoption with diverse models of implementation. This plenary session, moderated by ASAM President-Elect, Dr. Brian Hurley, will discuss the state of the research on telehealth for addiction treatment, innovative telehealth models, lessons learned during the pandemic, and implications for policies and practices going forward.

SCHEDULE

8:30 am – 8:40 am   Welcome to the Policy & Science Plenary
Brian Hurley, MD, MBA, DFASAM

8:40 am – 8:45 am   Acknowledgement of Public Policy Award Recipients
US Senator Tammy Baldwin (D-WI)
US Senator Mike Braun (R-IN)

8:45 am – 9:05 am   Updates on Telehealth Research
Tyler Oesterle, MD, MPH

8:55 am – 9:15 am   Innovative Telehealth Models
Nzinga A. Harrison, MD, FASAM

9:05 am – 9:15 am   Lessons Learned from Buprenorphine Telehealth
Rachel S. Wightman, MD

9:15 am – 9:25 am   Empowering Patients Through Telehealth
Vania P. Rudolf, MD, MPH, DFASAM

9:25 am – 9:55 am   Panel Discussion
Tyler Oesterle, MD, MPH
Nzinga A. Harrison, MD, FASAM
Rachel S. Wightman, MD
Vania P. Rudolf, MD, MPH, DFASAM
Jake Ketchum III
Brian Hurley, MD, MBA, DFASAM (Moderator)

9:55 am – 10:00 am   Closing Remarks
Brian Hurley, MD, MBA, DFASAM

SESSION MODERATOR

Brian Hurley, MD, MBA, DFASAM
President-Elect
American Society of Addiction Medicine
11:30 am – 12:30 pm
Focus Session – 1 CME
Continuum of Micro-dosing : Applying a Novel Technique Across a Healthcare System
Grand Ballroom West, Second Floor
Michelle Caffaney, PA-C; Dale J. Terasaki, MD, MPH; Kenneth Novoa, MD; Dayan D. Colon Sanchez, MD
Recently, a new strategy using micro-doses of buprenorphine was introduced that obviates the need for patients to taper off full-agonist opioids and experience opioid withdrawal prior to a buprenorphine induction. Denver Health Medical Center has developed a continuum of addiction care across the institution providing the opportunity for patients to transition to buprenorphine with the micro-dose technique in the inpatient, outpatient, and correctional settings. This “no-wrong-door” model allows patients to seek medications for opioid use disorder across our institution including on our inpatient units, outpatient clinics, and correctional facilities. This session reviews patient cases to illustrate the continuum and share pearls for providers on how to implement micro-dose buprenorphine inductions in multiple clinical settings.

Focus Session – 1 CME
Focus on Phenobarbital: Applications for Alcohol and Sedative-Hypnotic Withdrawal
Great Hall 4-6, Third Floor
Alaina R. Steck, MD, FASAM; JoAn Laes, MD; Timothy J. Wiegand, MD; FACMT, FAACT, DFASAM; Jeremiah D. Fairbanks, DO
Healthcare utilization for alcohol, sedative-hypnotic use, and withdrawal has increased significantly during the COVID-19 pandemic while simultaneously healthcare resources have become strained and increasingly limited. During this time, phenobarbital has gained increased attention as a favorable treatment option for both alcohol and sedative-hypnotic withdrawal. This session will utilize case-based discussion by an expert panel to address emerging questions about phenobarbital use in the inpatient, emergency department, and outpatient settings. There will be a review of the pathophysiology of alcohol and sedative-hypnotic withdrawal and the rationale for phenobarbital’s use in these situations, and some of the currently-used strategies, safety concerns, and evidence for efficacy.

Focus Session – 1 CME
Population Health Approach to Opioid Use Disorder: Can It Change The Game?
Atlantic Ballroom 2 & 3, Second Floor
Jill S. Warrington, MD, PhD; Robert London, MD; Jacquie Sheehy
The management of Opioid Use Disorder (OUD) has evolved over the past decade, allowing for the development of a more robust infrastructure, a broader team of trained health professionals, and the evolution of evidence-based clinical guidelines. Despite these advancements, OUD remains at a high prevalence, with routine reliance on acute care services and devastating patient outcomes. Core population health management principles, including risk stratification, care coordination, patient engagement strategies, and outcomes-based care management, can be utilized to create innovative strategies for the delivery of care for patients with OUD. This session will review Population Health Management tools as they can be applied to the management of OUD.

12:30 pm – 1:15 pm
Nurses, Nurse Practitioners, & Physician Assistants Meet-Up
ASAM Booth, Great Hall Foyer, Third Floor

12:30 pm – 1:30 pm
Lunch Bunch
Great Hall Foyer, Third Floor
Grab a bite and grab a seat! Meet people with your same interests, practice setting, profession, and career stage. Talk about topics that matter to you.

1:30 pm – 2:30 pm
Collaborative Session – 1 CME
Changes To Treatment Regulations During And After The COVID-19 Public Health Emergency
Great Hall 4-5, Third Floor
Yngvild K. Olsen, MD, MPH, DFASAM; Robert Baillieu, MD, MPH, FAAFP
Developed in Cooperation with Substance Abuse and Mental Health Services Administration (SAMHSA)
The COVID-19 Public Health Emergency necessitated policies that protected patients and providers while also maintaining access to services. Early in the pandemic, SAMHSA promulgated treatment flexibilities that waived regulatory restrictions on unsupervised methadone take-home medication, and, in conjunction with the DEA, established permissions for the initiation of buprenorphine without an in-person examination. As rates of overdose climbed, SAMHSA implemented policies that advanced harm reduction and expanded access to treatment. This session will engage participants in discussion about how treatment flexibilities were implemented during the difficult, early months of the pandemic, as well as policy initiatives and associated issues that may have benefitted providers and patients.

Workshop Session – 1 CME
Low-Dose Buprenorphine Inductions: Options and Innovations
Grand Ballroom East, Second Floor
Eowyn Rieke, MD, MPH; David Lawrence, MD, FASAM; Jennifer Hartley, PhD, MD, MSOM
The presence of fentanyl and fentanyl analogues (F/FA) in the US drug supply has contributed to dramatic increases in overdose deaths, as well as new challenges in Medications for Opioid Use Disorder (MOUD) care. This interactive workshop will include a review of the challenges of initiating buprenorphine for people who have been using fentanyl intentionally or unintentionally. This session will include an overview of innovative induction protocols used across the United States. Additionally, this session will examine two different protocols developed in an inpatient withdrawal management program, outcomes of these protocols in the inpatient and ambulatory settings with measures of treatment completion, successful ambulatory inductions, and patient experience. Challenges of buprenorphine maintenance in patients who have used fentanyl, including consideration of higher doses and other modifications of standard MOUD care will be discussed. After this workshop, participants will have a thorough understanding of the pharmacodynamics of fentanyl and buprenorphine and options to improve success of MOUD care for patients using fentanyl.

Focus Session – 1 CME
Mentoring Women Graduate Students Seeking a Career in Substance Use Disorder Research
Diplomat Ballroom 3-5, Second Floor
Barbara Andraka-Christoul, JD, PhD; Danielle Atkins, PhD, MPA; Yara M. Asi, PhD
To increase participation of women, especially women of color, in full time SUD research careers, an extracurricular mentoring program (MP) was developed and implemented at a large state university for five women PhD students during Spring 2021. This MP included internal group meetings, guest speaker panels, readings, and written assignments. Additionally, mixed methods were implemented to evaluate the MP’s impact on participant desire to seek a full time SUD research career, self-confidence in research, understanding of the research process, and awareness of the job application process. During this session, this MP’s development, structure, evaluation, and lessons learned will be reviewed. This session is recommended for anyone considering development or improvement of a mentoring program, inside or outside of a university context.
Focus Session – 1 CME

WTF - Methadone: What is the Future?

Atlantic Ballroom 2&3, Second Floor
Ruth A. Pote, MD, FASAM

Federal regulations for Opioid Treatment Programs (OTP) have been largely unchanged since 1973. This presentation reviews the history of methadone treatment for Opioid Use Disorder (OUD) with a specific analysis of the racial bias and health inequities perpetrated by 42CFR Section 8. Access to treatment with methadone is one strategy to reduce morbidity and mortality of OUD; yet current regulations create multiple barriers within OTPs. This presentation examines how the emergency order issued in 2020 to increase take-home bottles due to COVID-19 shifted methadone treatment delivery in the United States, the role of profit, and how to envision a more patient-centered and evidence-based approach to methadone delivery. The clinical evidence behind mandated group visits, required counseling, daily medication administration, and drug free toxicology is also discussed.

Focus Session – 1 CME

The Good, Bad and Ugly: Drug Testing in Liver Transplant Evaluations

Diplomat Ballroom 1&2, Second Floor
Soumya L. Pandalai, MD, FACP, DFASAM; JoAn Laes, MD; Robert C. Pueringer, MD; Stephanie T. Weiss, MD, PhD

The role of urine drug testing in patients undergoing liver transplant evaluation for alcohol-related liver disease is controversial. Most transplant centers require a period of abstinence despite limited data to support this practice. Consequently, biomarkers to detect alcohol and marijuana are often utilized without an adequate understanding of how abnormal levels impact clinical decisions like organ eligibility and listing. False accusations regarding recent use can lead to delayed medical care, relapse, disruption of the therapeutic rapport, and further highlight inequalities in healthcare. This session provides a review of the case studies that investigate current drug testing standards and identify clinical scenarios that result in unreliable results. Additionally, this session includes a discussion about verifying abstinence without drug testing and the potential uses of a novel test to detect THC metabolites.

Workshop Session – 1 CME

The Inner Work of Caring for Individuals with Severe Substance Use Disorders

Regency Ballroom, Second Floor
Janet J. Ho, MD, MPH; Katrina S. Nickels, MD; Julie Childers, MD, FASAM

Caring for patients who have substance use disorder (SUD) can be both extraordinarily rewarding and challenging, especially when patients have severe SUD complicated by adverse health events, repeat hospitalizations, and conditions refractory to multiple attempts at treatment. Addiction clinicians, who often have long-term relationships with patients advocating for care, can find it even more distressing when a patient’s SUD continues to worsen, despite best efforts at motivating and offering treatment. If left unexamined and unaddressed, clinician grief can potentially lead to maladaptive coping, compassion fatigue, and burnout. This session reviews tools to care for individuals with severe SUD by physicians with palliative and addiction medicine expertise and examines situations where patients may not recover. Additionally, this session provides a review of how being mindful of small changes, such as the utilization of team debriefing and processing, can address clinician burnout and encourage practitioners to remain present and maintain hope even amidst the most challenging cases.
3:00 pm – 4:00 pm
Focus Session – 1 CME
Great Hall 4-6, Third Floor
Sarah E. Wakeman, MD; Joshua D. Lee, MD, MSc; Jennifer McNeely, MD, MPH
This is an annual review of the highest impact, peer-reviewed articles across the field of Addiction Medicine for 2021-2022. The review is composed of brief journal club presentations of each article, organized under the ASAM Principles of Addiction Medicine textbook chapter headings: neurobiology, epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, harm reduction, criminal justice, dual diagnoses, and pharmacologic and behavioral interventions. The goal of this session is to provide the learner with a concise, structured, critical summary of the important recently published scientific papers. All of the core Principles chapters are covered, using the highest rated articles within these topics.

Focus Session – 1 CME
How iOAT Care Could Be Improved?: Providers Perspectives on Clients’ Needs
Diplomat Ballroom 3-5, Second Floor
Eugenia Oviado-Joekes, PhD; Donald Scott MacDonald, MD
Rapid expansion of effective treatments for opioid use disorder (OUD) is more important now than ever. Understanding client preferences for iOAT can inform program design(s) that optimize uptake and expansion, promoting person-centered care in addiction. Including the providers’ perspectives in these processes could enhance understanding of how iOAT care could be improved to better meet clients’ needs. This session offers an examination into iOAT and providers’ perspectives such as system-level considerations to advance the provision of low barrier, access to diverse iOAT medications, non-punitive approaches, training, and easing regulatory constraints.

Focus Session – 1 CME
Leveraging Community Harm Reduction Services to Provide Mobile Primary Care/SUD Treatment
Atlantic Ballroom 2&3, Second Floor
Jennie Jarrett, PharmD, BCPS, MedEd; Eden G. Keller, PharmD; Sarah Messmer, MD
This session provides a review of an innovative, interprofessional practice model integrating mobile primary care services and a low threshold opioid treatment into a longstanding mobile harm reduction and syringe exchange program in urban underserved communities. Additionally, this session examines the unique challenges to mobile primary and substance use disorder care, including partnerships with opioid treatment programs, interacting with the DEA, and collaborating with harm reduction programs to support patients’ treatment goals. Participants will gain a better understanding of emerging mobile treatment models, integrating interprofessional education and patient care, and engaging in harm reduction within underserved populations.

Focus Session – 1 CME
Methamphetamine Use Disorder in Pregnancy
Grand Ballroom East, Second Floor
Charles W. Schauberger, MD, MS, FACOG, FASAM; Marcela Smid, MD, MA, FACEP, DFASAM
As methamphetamine use in the United States has increased, 1% of all deliveries are complicated by methamphetamine use representing over 37,000 maternal–infant dyads. The processes of prenatal and addiction care for individuals with methamphetamine use are made complex by insecure housing, frequent involvement with the criminal justice system and other barriers. This session will provide a summary of the literature related to methamphetamine use in pregnancy and in the postpartum period. Additionally, recommendations for prenatal and addiction care for pregnant and postpartum individuals will be examined and the models of integrated care that may prove useful for future investigation will be discussed.

Workshop Session – 1 CME
Palliative Care for Patients with Substance Use Disorders: Challenges and Opportunities
Grand Ballroom West, Second Floor
Yara Moustafa, MD, PhD; Faraqoq Mohyuddin, MD
People with substance use disorders are more likely to develop chronic and life-threatening conditions and die earlier than the general population. Some of the contributing factors include barriers to healthcare access, negative healthcare experiences, poor social support due to stigma, and other drug-related morbidities and mortalities. This session provides an examination of use case studies and literature review to familiarize participants with the unique challenges faced by this population, especially those with co-morbid conditions. Participants will learn about patient barriers to palliative and hospice services access, as well. In small group discussion format, participants will identify key factors that undermine early access to services, particularly the role of physicians’ countertransference.

4:00 pm – 4:30 pm
Refreshment Break
Grand Ballroom Foyer, Second Floor
Meet the JAM Editors
ASAM Booth, Great Hall Foyer, Third Floor

Students and Ruth Fox Scholars Meet-Up
ASAM Booth, Great Hall Foyer, Third Floor

4:30 pm – 5:30 pm
Focus Session – 1 CME
Development of The ASAM Criteria Intake Assessment: A Free, Paper-Based, Interview Form
Atlantic Ballroom 2&3, Second Floor
Anne B. Lee, LCSW; Thomas E. Freese, PhD; R. Corey Waller, MD, MS, FACEP, DFASAM
The ASAM Criteria Intake Assessment is intended as a guide to multidimensional assessment of individuals with Substance Use Disorders (SUDs) and as a guide to the conceptual approach of the ASAM Criteria decision logic. It is designed to assist Level of Care (LOC) decision-making for adults who are seeking treatment. The ASAM Criteria Intake Assessment Form for Adults has two primary components. The first component is a set of questions that guides the interviewer to establish risk ratings for the six domains of The ASAM Criteria. The second component of the form includes a summary sheet and Level of Care Guide where the interviewer summarizes information from the interview questions and uses the risk ratings from the six dimensions and guidance embedded in the assessment form to select the appropriate LOC. This session will describe the development of the tool and the results of a small feasibility study. Additionally, this session will provide an overview of the assessment, discuss scoring guidance, and explore information and resources for anyone who would like to implement the tool locally.
herself. This presentation provides participants with a review of the unique pharmacologic properties of extended-release buprenorphine, logistical issues obtaining the medication, administration tips, common patient concerns such as getting "too much" or "too little" medication, injection site complications, utilizing blood levels, and limited sublingual buprenorphine supplementation. Additionally, discussion will include novel dosing protocols, use in specific populations, weaning, and social/logistical challenges that may arise with using extended-release buprenorphine.

Focus Session – 1 CME
Frontiers in ED Addiction Care
Regency Ballroom, Second Floor
Hannah Snyder, MD; Arianna D. Campbell, PA-C; Aimee Moulin, MD, MAS; Elizabeth Jane Johnson, MD
This highly interactive session is focused on how emergency departments can innovate in addiction care. Presenters will take a practical approach to implementation of ED buprenorphine in the fentanyl era, treatment of alcohol and stimulant use disorder, and harm reduction in ED settings. The session will feature clinicians from across California, and share preliminary findings from the California Bridge Centers of Excellence quality improvement group. Participants will access practical toolkits and handouts that will allow them to implement at their own facilities.

Focus Session – 1 CME
Gaming Disorder 101: How to Distinguish Passion from Problem
Grand Ballroom East, Second Floor
Emily Brunner, MD; Cam Adair
Gaming disorder is a condition recognized by the World Health Organization (WHO) and is included in the ICD-11. While gaming disorder is increasingly discussed in popular media, it is often done so without a strong scientific underpinning. This session provides a review of current evidence behind best practices for gaming disorder identification, treatment, prevalence, and risk factors associated with gaming disorder development.

Workshop Session – 1 CME
Provider Bias In The Treatment Of Opioid Use Disorder
Grand Ballroom West, Second Floor
Dana Lehman, PsyD; Christian S. Credle, PsyD
Since the start of the opioid epidemic, significant financial and medical resources have been used to combat the crisis. Despite this, the data shows that the rates of abuse, overdose, and death continue to skyrocket, particularly within communities of color. Reasons for this include provider bias, fear of legal consequences, stigma, and lack of access to culturally competent healthcare. It is imperative that medical and mental health providers working to fight this epidemic examine the role internalized bias plays in fostering minority opioid users receiving substandard treatment. This presentation provides participants with a supportive space to discuss ideas and concerns regarding these issues.

Focus Session – 1 CME
The Role of Opioid Metabolic Pathways in Interpreting Urine Drug Testing Results
Great Hall 4-6, Third Floor
Stephanie T. Weiss, MD, PhD; JoAn Laes, MD; Lewis S. Nelson, MD; Soumya L. Pandalal, MD, FACP, DFASAM
This session provides an in-depth review of the principles of urine drug testing, both types of drug screening methods, opioid metabolite pathways, and potential pitfalls and interpretation errors that can occur with urine drug testing. Participants will learn about the possibility of misinterpretation of both urine drug screens and confirmatory liquid chromatography-mass spectrometry testing due to insufficient knowledge of the testing method and compound pharmacology involved. Participants in this session will hone their urine drug testing interpretation skills and clarify when further interpretation assistance is required.

8:00 pm – 9:00 pm
General Session – 1 CME
Black Men in White Coats: From Awareness to Action
Regency Ballroom, Second Floor
Dale Okorodudu, MD; Louis E. Baxter, Sr, MD, DFASAM; Stephen M. Taylor, MD, MPH, DFAPA, DFASAM
In 2013, the Association of American Medical Colleges released an alarming report informing the nation that the already low number of Black men applicants to medical school was decreasing. In 2021, this trend started to change as the global pandemic has contributed to a growing recognition of the effects of health disparities and the significant shortage of health care professionals. While the latest data is encouraging, there is still much more work to be done to increase the representation of Black men in the medical profession. Panelists in this session will show clips from the documentary, Black Men in White Coats, and have a frank discussion about the disparities, stereotypes, and stigma associated with Black men and the health care profession. Panelists will also explain how medical schools and others in the field can get involved in addressing this crisis.

9:00 pm – 10:00 pm
Mutual Help
302 Conference Room, Third Floor
Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.

SUNDAY, APRIL 3, 2022
6:30 am – 7:30 am
Mutual Help
302 Conference Room, Third Floor
Held each morning and evening of the conference, these peer-run addiction problem-specific support groups are open to any registrant.

7:00 am – 8:00 am
Continental Breakfast
Grand Ballroom Foyer, Second Floor
Ruth Fox Endowment Scholarship Recipients Meeting
303 Conference Room, Third Floor
7:00 am – 12:00 pm
ASAM Registration & Education Desk Open
Grand Ballroom Foyer, Second Floor
8:00 am – 9:00 am
**Workshop Session – 1 CME**
**Changing the Focus: Envisioning Alcohol Use Through a Harm Reduction Lens**
Atlantic Ballroom 3-5, Second Floor
Rachel B. King, MD; Alyssa Peterkin, MD

Alcohol-related death is the third most preventable cause of death in the United States. Historically, the medical field has viewed abstinence as the primary goal when addressing alcohol-related problems. However, approaches that focus on abstinence are at risk of excluding persons who may benefit from education on strategies to mitigate risks associated with alcohol use. This session will review practical strategies that reduce harm related to alcohol use. Participants will gain practical skills through small group, case-based discussions that demonstrate feasibility of implementing harm-reduction strategies to improve the health of persons using alcohol.

9:00 am – 9:30 am
**Workshop Session – 1 CME**
**Do AA and NA work? If So, How Do They work?**
Atlantic Ballroom 2&3, Second Floor
Paul H. Earley, MD; Mel Pohl, MD, DFASAM

Addiction medicine has made great strides in adopting a strong evidence base in the past thirty years. Along the way, however, many addiction professionals have fallen under the incorrect notion that AA and other 12-Step programs provide a gathering of individuals in recovery but have no proven mechanisms of efficacy in sustaining disease remission. After a very brief didactic presentation, a mock AA meeting will be staged with real-time audience participation. Using start/stop timing, methods of efficacy from the scientific literature will be highlighted as they occur. Subsequent discussion will deepen audience appreciation as to how AA strengthens relapse prevention skills, engenders behavioral and cognitive change, and induces healthy changes in personality.

9:30 am – 10:30 am
**Focus Session – 1 CME**
**Facts About Fentanyl**
Regency Ballroom, Second Floor
Joan E. Harris, MD; Alaina R. Steck, MD, FASAM; Robert C. Pueinger, MD; Lewis S. Nelson, MD

The COVID-19 pandemic spurred the largest increase in U.S. drug overdose deaths in history with a 30% increase between 2019 and 2020. Much of this increase in overdose deaths continues to be driven by fentanyl and fentanyl analogs. This session provides a review of trends, clinical management, epidemiology of the opioid epidemic, including recent changes in exposure to fentanyl, fentanyl analogs, and other substances in pressed, illicitly-manufactured pills. Additionally, this session examines harm reduction strategies, such as fentanyl test strips, updated approaches to drug testing, and considerations regarding naloxone reversal and buprenorphine induction for patients who predominately use fentanyl.

**Focus Session – 1 CME**
**Cannabis Conversations**
Regency Ballroom, Second Floor
Michael F. Weaver, MD, DFASAM; John A. Hopper, MD, DFASAM

Cannabis is becoming more popular and a majority of states in the U.S. have passed legislation allowing for medical use of cannabis or decriminalization of recreational use. This session provides a review of the different cannabis products available in the U.S. and the risks and benefits that pertain to cannabis use. The presenters will compare and contrast regulations in the states with and without medical cannabis or decriminalization of cannabis, and reviews panelist clinical expertise with patients experiencing use and complications of cannabis. The emphasis will be on clinical issues, especially discussing the risks associated with cannabis use.

3:00 pm – 4:00 pm
**Focus Session – 1 CME**
**Improving Patient Outcomes Through Fully Integrated Peer Recovery Support Services**
Atlantic Ballroom 1, Second Floor
Alan Gordon, MD; Michael M. Litterer, CHES, CPS, FHELA; Elliott Liebling, MPH; Marc A. Milano, MD, FACEP

This session will provide a review of the history of a Fully Integrated Peer Recovery Support Services program and an examination into the current state of the program’s infrastructure, implementation, operation, and metrics. Additionally, the future direction of the program will be discussed and lessons learned, challenges, and triumphs will be highlighted. This session will also provide guidance for any professionals seeking to implement similar programs in their facility or institution.
**Workshop Session – 1 CME**

**Loneliness, Loss and Love: How to Keep Going in 2022**

Diplomat Ballroom 3-5, Second Floor

Emily Brunner, MD; Stephen M. Delisi, MD; Princess Drake, MS, PsyD

This session will provide a review of the increase in patient and clinician grief and loneliness and how these impact health and recovery, especially amidst the coronavirus pandemic. Strategies to mitigate loneliness at both an individual and community level will be reviewed and a practical tactic on how to provide a safe space to process loneliness and grief/loss will be examined. Additionally, there will be an exploration of the shared neurobiology and neuroscience of loneliness, grief/loss, and substance use disorders (SUD) to better understand patients who present with grief/loss and SUD.

**Focus Session – 1 CME**

**Moving Beyond Naloxone: Integrating Harm Reduction Into Office-Based Addiction Treatment**

Regency Ballroom, Second Floor

J. Deanna Wilson, MD, MPH; Stephanie P. Klipp, RN, CARN, CAAP, CRS; Divya Venkat, MD; Elizabeth Cuevas, MD

As the opioid epidemic continues to rage on with unprecedented overdose death rates in the United States, there is a need to have broader engagement strategies that reduce risk and mortality from substance use. This session will review patient-centered strategies and best practices to integrate harm reduction practices, education, and counseling into office-based addiction treatment. Participants will explore opportunities on how to counsel patients on overdose risk reduction, discuss provider scripts for safer injection techniques, and review clinical guidelines for HIV and HCV prevention as well as HCV treatment. This session also includes a review of strategies related to prescribing buprenorphine using a harm-reduction lens and how this influences logistics, such as urine drug screens, counseling requirements, and clinical documentation.

**Workshop Session – 1 CME**

**Stories of Our Ancestors: The impact of Culture, Race, Trauma on Addiction**

Diplomat Ballroom 1&2, Second Floor

Carolyn C. Ross, MD, MPH, CEDS

Research on the impact trauma has on families and offspring goes back decades and includes trauma caused by war, genocide, class struggles, and racism. Helping professionals, such as psychologists, therapists, and other care experts tend to lack understanding that these kinds of traumas can have on patients with Substance Use Disorders. This session examines the treatment of trauma based on cultural identity or race and includes strategies clinicians can use with patients with historical, international, or racial trauma to help patients build resilience in their recovery process.

**10:30 am – 11:00 am**

**Refreshment Break**

Grand Ballroom Foyer, Second Floor

**11:00 am – 12:00 pm**

**Focus Session – 1 CME**

**A Telemedicine Bridge Clinic Successfully Engages Patients in Buprenorphine Treatment**

Atlantic Ballroom 2&3, Second Floor

Michael J. Lynch, MD

This session will examine the development and implementation of a novel telemedicine bridge program in Pennsylvania that provides rapid direct access to low-barrier addiction medical treatment for patients throughout the state while long-term care is identified. Patient demographics, referral patterns, and preliminary outcomes for the first 550 patients evaluated from April 2020 through December 2021 will be described and logistics, programmatic guidelines, and lessons learned will be reviewed. Future strategies to incorporate telehealth in addiction care will be considered as well as opportunities for legislative advocacy.

**Focus Session – 1 CME**

**Toxicology Topics: Drug Levels for Buprenorphine: Efficacy, Diversion, and Compliance**

Regency Ballroom, Second Floor

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM; JoAn Laes, MD; Hiroko Furo, MD, PhD, MA; MS; Soumya L. Pandalai, MD, FACP, DFASAM

This session will address toxicology topics through a combined, interactive, case-based and didactic session led by a panel of medical toxicology and addiction medicine expert faculty. Different buprenorphine and naloxone tests, the interpretation of results, impact on patient management, and available literature in this area will be reviewed and discussed.

**Workshop Session – 1 CME**

**Considérations in Referring to Mutual Aid Groups: Legal, Ethical, Clinical & Pragmatic**

Diplomat Ballroom 1&2, Second Floor

Joseph Gerstein, MD, FACP

Free mutual aid groups are now available with a variety of ideologies, styles, world views, focus of control preferences, levels of acceptance of MAT/OAT, levels of supporting evidence of efficacy, and goals. In the era of the online availability of free mutual aid group programs, legal, clinical, ethical, and practical considerations should be taken into account so that referrals match patients with programs appropriately. More attention given to this paradigm will result in an increase in more beneficial referrals.

**Workshop Session – 1 CME**

**Strengthening Substance Use Prevention Messaging for Youth in the Wake of COVID-19**

Diplomat Ballroom 3-5, Second Floor

Stephanie Swanson, MPH; Pam Pietrusewski, MA

The COVID-19 pandemic has caused incredible disruption in the lives of young people during a time when they are already vulnerable in their growth, development, and identity. To address the rising concern of substance use during the pandemic, the National Council created a comprehensive message guide and toolkit based upon findings from national assessments of youth and youth-serving providers, key informant discussions, and message testing. The focus of this workshop is the implementation of substance use prevention messaging with middle and high school youth. The continuum of substance use requires a comprehensive approach and early intervention is needed to alleviate work for treatment providers. Participants will have access to a complementary toolkit including clinical and operational resources to support youth-serving providers.

**Workshop Session – 1 CME**

**Wake of COVID-19**

Regency Ballroom, Second Floor

Stephanie Swanson, MPH; Pam Pietrusewski, MA

The COVID-19 pandemic has caused incredible disruption in the lives of young people during a time when they are already vulnerable in their growth, development, and identity. To address the rising concern of substance use during the pandemic, the National Council created a comprehensive message guide and toolkit based upon findings from national assessments of youth and youth-serving providers, key informant discussions, and message testing. The focus of this workshop is the implementation of substance use prevention messaging with middle and high school youth. The continuum of substance use requires a comprehensive approach and early intervention is needed to alleviate work for treatment providers. Participants will have access to a complementary toolkit including clinical and operational resources to support youth-serving providers.

**Official Close of the ASAM 53rd Annual Conference! See you next year from April 13 - 16, 2023!**
Congratulations to ASAM’s award recipients! Be inspired by these outstanding leaders in addiction medicine as they receive recognition at the sessions as indicated below.

**PRESIDENT’S RUTH FOX RECEPTION FOR Awardees AND DONORS (By Invitation Only)**

*Thursday, March 31 | 6:30 pm - 8:00 pm*

**ASAM Training Directors Award**

*Louis E. Baxter, Sr, MD, DFASAM*

The ASAM Annual Training Directors Award recognizes and honors an individual who has demonstrated outstanding training in the evaluation, treatment, research and teaching of substance use disorders.

**ASAM Media Award**

*Dale Okorodudu, MD*

Recognizes and honors an individual who has broken down barriers produced by prejudice, exclusion or injustice in healthcare.

**OPENING SCIENTIFIC PLENARY**

*Friday, April 1 | 8:30 am – 10:00 am*

**R. Brinkley Smithers Distinguished Scientist Award**

*Chinazo O. Cunningham, MD, MS, FASAM*

Recognizes and honors an individual who has made highly meritorious contributions to advancing the scientific understanding of alcoholism, its prevention, and treatment.

**ASAM Presidential Award**

*Richard A. Rawson, PhD*

Recognizes and honors an individual for outstanding dedication and service in addressing addiction issues or promoting education, training or awareness of the specialty of addiction medicine.

**BIG IDEAS PLENARY SESSION**

*Friday, April 1 | 1:00 pm – 2:30 pm*

**John P. McGovern Award**

*Kelly J. Clark, MD, MBA, DFAPA, DFASAM*

Recognize and honor an individual who has made highly meritorious contributions to public policy, treatment, research, or prevention which has increased our understanding of the relationship of addiction and society.

**ASAM Leadership Award**

*Paul H. Earley, MD, DFASAM*

The Former Presidents/Leadership Award honors individuals who have served as national president of the American Society of Addiction Medicine. It is bestowed upon the completion of their term as the Past President, by which time the recipient has served nearly a decade on the presidential track of the ASAM Board.

**ASAM Annual Award**

*Timothy Wiegand, MD, FACMT, FAICT, DFASAM*

Recognize outstanding contributions to the growth and vitality of our Society, for thoughtful leadership in the field, and for deep understanding of the art and science of addiction medicine, and for expanding the frontiers of the field of addiction medicine and broadening our understanding of the addictive process, through research and innovation.

**ASAM Educator of the Year Award**

*David Mee-Lee, MD, DFASAM*

Recognizes and honors an individual who has made outstanding contributions to ASAM’s addiction medicine education.

**THE STATE OF THE ORGANIZATION**

*Saturday, April 2 | 7:45 am – 8:15 am*

**ASAM Public Policy Award**

*US Senator Tammy Baldwin (D-WI)*

**US Senator Mike Braun (R-IN)**
ASAM ABSTRACT AWARD RECIPIENTS

Best Overall Abstract Submission
Kristin Prewitt, MD, MPH
To recognize the primary author of the highest scoring submitted poster abstract.

ASAM Abstract Award: Fellow-in-Training
Lea Selitsky, MD, MPH
Fellowship Program: Johns Hopkins University/Bayview Medical Center.
Program Director: Darius Rastegar, MD
To recognize a poster’s primary author who is currently enrolled in a medical fellowship program.

ASAM Abstract Award: Representation in Research
Maria Gabriela Rodriguez
To recognize a poster’s primary author who is from racial and/or ethnic underrepresented minority backgrounds (i.e., American Indian or Alaska Native, Black or African American, Native Hawaiian or Pacific Islander, Non-Caucasian Hispanic or Latinx).

ASAM Abstract Award: Resident
Brigid Adviento, MD, MPH
To recognize a poster’s primary author who is currently enrolled in a medical residency program.

ASAM Abstract Award: Underserved Population
Nia Bhadra-Heintz, MD
To recognize the primary author of the highest scoring submitted poster abstract that addresses research on an underserved population (characterized by race, ethnicity, age, geography, gender, and/or sexual orientation).

ASAM Abstract Award: Associated Professionals
Casey Tak, PhD, MPH
To recognize a poster’s primary author who is one of the following types of professional: Certified Addictions Registered Nurse (CARN), Clinical Nurse Specialist in Psychiatry (Psych-CNS), Clinical Psychologists (PhD or PsyD), Doctor of Pharmacy (PharmD), Licensed Professional Counselor (LPC), Doctor of Dental Surgery (DDS), Doctor of Nursing Science (DNSP or equivalent), Doctor of Philosophy (PhD), Doctor of Veterinary Medicine (DVM), Licensed Alcohol and Drug Counselor (LADC), Licensed Marriage and Family Therapist (LMFT), Nurse Practitioner (NP), Physician Assistant (PA), Registered Nurse (RN), Social Workers, or Doctor of Dental Medicine (DMD).

ASAM ABSTRACT HONORABLE MENTIONS

Honorable Mention: Best Overall
Caroline Wunsch, MD

Honorable Mention: Associated Professional
Vinita Sharma, PhD, MPH, CPH, CHES

Honorable Mention: Associated Professional
Monica Tomlinson, PhD

Honorable Mention: Fellow-in-Training
Javier Ponce Terashima

Honorable Mention: Representation in Research
Loretta O. Akpala, MD

Honorable Mention: Representation in Research
Darlene I. Santiago Quiñones, PhD, MS

Honorable Mention: Resident
Darien Stratton, MD, MA

Honorable Mention: Underserved Population
Maria C. Mejia, MD, MPH, FACPM

“Always wonderful to meet up with colleagues, learn some more and walk away inspired and motivated to be a more skilled clinician/researcher than what I was yesterday.”
DISTINGUISHED FELLows, RUTH FOX SCHOLARS & NIDA YOUNG INVESTIGATOR TRAVEL AWARD RECIPIENTS

Congratulations! ASAM is proud to acknowledge the following recipients.

2022 Distinguished Fellows

Distinguished Fellows are chosen based upon an outstanding and long sustained demonstration of top-ranking competence in the field of addiction medicine, exceptional professionalism, consummate integrity, demonstrated service, significant contribution, and noted leadership.

Nicholas Athanasiou, MD, MBA, DFASAM
Thomas J. Brady, MD, DFASAM
Megan Buresh, MD, DFASAM
Indra K. Cidambi, MD, DFASAM
Alta DeRoo, MD, DFASAM
JoAn Laes, MD, FACMT, DFASAM
Jonathan C. Lee, MD, DFASAM
Soumya L. Pandalai, MD, FACP, DFASAM
John A. Peterson, MD, DFASAM
Arwen E. Podesta, MD, DFASAM

2022 Ruth Fox Scholars

Ruth Fox Scholars are physicians-in-training with demonstrated academic excellence, leadership potential, interest in additional addiction medicine education, and a desire to spread this education to other physicians-in-training.

Daniel Ageze, MD
Karen Antwiler, MD
Michael Argenyi, MD
Cecily Barber, MD
Paul Christine, MD
Norris Curl, MD
Mallory Davis, MD
Daniel Hernandez, MD
Illana Hull, MD
Rachel Knight, MD
Clare Landefeld, MD
Jessica Matthews, MD
Katrina Nickels, MD
Ogorchukwu Faith Omede, MD
Jarratt Pytell, MD
Kara Ryan, MD
Andrea Silva, MD
Kento Sonoda, MD
Leslie Suen, MD
Francesco Tani, MD

2022 NIDA Young Investigator Travel Award Recipients

The NIDA Young Investigator Travel Award encourages young investigators who are within 5-10 years of earning their PhD, MD, or DO degree entering the fields of addiction research and practice. The award’s focus is to provide a training experience for young investigators in the area of drug addiction and infectious disease research, through conference fellowships at The ASAM Annual Conference.

Hamed Ekhtiari, MD
Kevin Xu, MD
### POSTER VIEWING SESSION 1

<table>
<thead>
<tr>
<th>Poster 1</th>
<th>Expanded Protective Custody Laws Did Not Increase EMS Transport After Opioid Overdoses – Alexander Zozula, MD, FAEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 2</td>
<td>Intravenous Buprenorphine for Opioid Withdrawal: A Case Series – Julia B. Nath, MD</td>
</tr>
<tr>
<td>Poster 3</td>
<td>Using Academic Detailing for Educational Outreach to Reduce Opioid Prescribing Rates – Mohab Ali, MD</td>
</tr>
<tr>
<td>Poster 4</td>
<td>Cannabis-Induced Atypical Stress Cardiomyopathy: A Case Report – Wendy Lin, MD; Karen D. Antwiler, MD, MBBS</td>
</tr>
<tr>
<td>Poster 5</td>
<td>Prevalence and Predictors of MAT Among Reproductive-Aged Women – Jennifer Bello Kottenstette, MD</td>
</tr>
<tr>
<td>Poster 6</td>
<td>Substance Abuse Research Education and Training Program (SARET) – Mia Malone; Kathleen Hanley, MD</td>
</tr>
<tr>
<td>Poster 7</td>
<td>Naltrexone Prescribing from the Emergency Department – Eva Duvalyan, PharmD; Winnie Fan; Sally Graglia, MD MPH</td>
</tr>
<tr>
<td>Poster 8</td>
<td>Relief Is Hard to Reach: Barriers to Medical Cannabis in Bronx, NY – Jayabhargav Annam; Jacqueline Labins; Julia Arnsten, MD, MPH</td>
</tr>
<tr>
<td>Poster 9</td>
<td>Mammography Screening Disparities in Urban Patients with Substance Use Disorder – Lorien Shack, MD</td>
</tr>
<tr>
<td>Poster 10</td>
<td>Individuals Diagnosed with an Alcohol Use Disorder: Who Receives What Healthcare Advice? – Vinita Sharma, PhD, MPH, CPH</td>
</tr>
<tr>
<td>Honororable Mention: Associated Professional</td>
<td></td>
</tr>
<tr>
<td>Poster 11</td>
<td>Kratom (Mitragyna Speciosa) and Polysubstance Use Patterns: A Latent Class Analysis – Alyssa M. Falise, MSPH</td>
</tr>
<tr>
<td>Poster 12</td>
<td>Predictors of Buprenorphine Continuation Among Postpartum People With Opioid Use Disorder – Hannah Shadowen, MPH; Andrea Gataric</td>
</tr>
<tr>
<td>Poster 13</td>
<td>Social Determinants of Health &amp; Substance Use Disorder Treatment: Scoping Literature Review – Andrew Alberth, MPH; Elisabeth Kato, MD, MRP; Sebastian T. Tong, MD, MPH, FASAM</td>
</tr>
<tr>
<td>Poster 14</td>
<td>Epigenetic Clocks in Brain and Blood of Individuals with Substance Use Disorder – Brenda Cabrera Mendoza, MD, PhD</td>
</tr>
<tr>
<td>Poster 15</td>
<td>Improving Intranasal Naloxone Distribution for Harm Reduction in Emergency Departments – Spencer M. Gardner, MS</td>
</tr>
<tr>
<td>Poster 16</td>
<td>Buprenorphine Pre-Hospital: A Review of 3 Years of MAT Induction by EMS – Joseph M. Martin, MD, FASAM</td>
</tr>
<tr>
<td>Poster 17</td>
<td>Rural and Urban Michigan Pharmacists’ Perceptions of Buprenorphine for Opioid Use Disorder – Victoria Tutag Lehr, PharmD</td>
</tr>
<tr>
<td>Poster 18</td>
<td>Real-World Outcomes With MOUD in Uninsured Patients: Inpatient to Outpatient Transitions – George C. Coleman, MD; Michael Baca-Atlas, MD, FASAM; Joseph B. Williams, MD, FASAM</td>
</tr>
<tr>
<td>Poster 19</td>
<td>Successfully Enrolling a Prospective Cohort With Opioid Use Disorder and Serious Infections – Loretta O. Akpala, MD; Benjamin I. Bearnot, MD</td>
</tr>
<tr>
<td>Honororable Mention: Representation in Research</td>
<td></td>
</tr>
<tr>
<td>Poster 20</td>
<td>U.S. County Jail Care of Incarcerated Pregnant Persons with Opioid Use Disorder – Kelley Benck; Kathryn M. Nowotny, PhD</td>
</tr>
<tr>
<td>Poster 21</td>
<td>Leveraging Community in Addiction Recovery for Permanent Supportive Housing Residents – Saifyya Zaidi; Daphne Hancock, MPH; Nicholas J. Christian, MD, MBA</td>
</tr>
<tr>
<td>Poster 22</td>
<td>New OTP Patient Retention Was Unchanged by COVID Take Home Methadone Increases – Aaron D. Greenblatt, MD; Annabelle M. Belcher, PhD</td>
</tr>
<tr>
<td>Poster 23</td>
<td>Patient Attitudes Toward Open Label Placebo Treatment for Opioid Use Disorder – Timur Suhail-Sindhu, MD; Annabelle M. Belcher, PhD; Aaron D. Greenblatt, MD</td>
</tr>
<tr>
<td>Poster 24</td>
<td>A Multipronged Approach to Improving Linkage to Outpatient Substance Use Treatment – Kimberly B. Cartmill, MD</td>
</tr>
<tr>
<td>Poster 25</td>
<td>Family Dependency Drug Court Service Modifications During COVID-19 – Rachel K. Totaram, MHA; Fatema Z. Ahmed, MHA</td>
</tr>
<tr>
<td>Poster 26</td>
<td>Health Care Utilization Outcomes of a Comprehensive Program for Perinatal Substance Use – Valerie S. Ganetsky, PharmD, MSc; Kaitlan Baston, MD, MSc, DFASAM; Iris Jones, LPC, LCADC, CCS, NCC</td>
</tr>
<tr>
<td>Poster 27</td>
<td>Real-world Evaluation of an Injectable Extended-Release Buprenorphine Program – Jessica Heil, MSPH; Valerie S. Ganetsky, PharmD, MSc</td>
</tr>
<tr>
<td>Poster 28</td>
<td>Project BETTER Acceptability: Technology-Based Educational Intervention for Women on MOUD – Sarah Martin; Anna B. Parlier-Ahmad, MS</td>
</tr>
<tr>
<td>Poster 29</td>
<td>COVID-19 Implications in Mental Health and Opioid Use Disorder Treatment: Qualitative Study – Javier Ponce Terashima, MD</td>
</tr>
<tr>
<td>Honororable Mention: Fellow-in-Training</td>
<td></td>
</tr>
<tr>
<td>Poster 30</td>
<td>Triangulating Substance Use, Treatment, and Mortality Trends Using Multiple Sources – Riley D. Shearer, MSc</td>
</tr>
</tbody>
</table>
Scientific Posters | Friday, April 1

Poster 31 – COVID-19 Vaccine Uptake and Attitudes Among People with OUD – Catherine C. Gannon; Emade Ebah, MPH

Poster 32 – Buprenorphine Treatment Disparities: The Role of the Specialty System and Insurance Status – Kevin Y. Xu, MD, MPH

Poster 33 – Cannabis Legalization and Adolescent Substance Use – Devika Bhatia, MD

Poster 34 – Opioid Use Disorder Treatment Training Impacts Future Residents’ Attitudes and Perceptions – Julie A. Kmiec, DO

Poster 35 – Comparing In-Person and Remote Substance Use Treatment Outcomes Before and During COVID-19 – Monica F. Tomlinson, PhD

Poster 36 – Community-Based Interventions for OUD in Black Churches: A Qualitative Study – Ebony F. Caldwell, MD, MPH

Poster 37 – Adolescent Addiction Medicine Tele-Consult Services within School-Based Health Centers – Caleb M. Lusk, MD, MPH

Poster 38 – Adolescent Substance Use: A Mixed Methods Assessment – Kenneth W. Verbos, MD, MPH, MSc

Poster 39 – Long-Term Treatment Benefit of BUP-XR for Patients Struggling to Abstain from Opioids – Daniel Rutrick, MD

Poster 40 – Critical Incidents in Colorado OTPs: Comparing Early COVID-19 Pandemic to Previous Years – Cole Bortz; Isaac Armistead, MD, MPH

Poster 41 – Advancing Patient-Centered Research and Care Through Journey Mapping: EMPOWER Project – Nichole Nidey, PhD

Poster 42 – Association Between Healthcare Costs and MOUD Treatment Linkage for Medicaid FFS Enrollees – Mohammad Usama Toseef, PhD

Poster 43 – Medication for Opioid Use Disorder Amongst People of Color in Residential Treatment – Abigail Frields, MSN, APRN, FNP-C, PMHNP-BC

Poster 44 – Trends in Buprenorphine Treatment Disparities During the COVID Pandemic in Massachusetts – Sarah E. Wakeman, MD


Poster 46 – Race and Ethnicity Concordance in Recovery Coaching – Aleta D. Carroll, LMHC, MBA; Jordanna L. Monteiro, MPH

Poster 47 – Implementing Substance Use Prevention Programming in Rural Utah During COVID-19 – Stacey MacArthur, PhD; Paige Wray, MS; Claire Warnick, MA

Poster 48 – Opioid Agonist Therapy Improves HIV/TB Outcomes Among PWUD/PWID in Mbeya, Tanzania – Chaita Chai, MD; Eniko E. Akom, MD, MPH

Poster 49 – Comparing Outcomes of MOUD Maintenance vs. Detoxification in Pregnant Patients with OUD – Danielle M. Anderson, MD

Poster 50 – Medical Mistrust and Care Expectations Among Black Patients Seeking Addiction Treatment – Nia M. Bhadra-Heintz, MD, MS; Jennifer K. Samiec

Poster 51 – The Female Offender Re-Entry Movement (FOR-Me): Increasing Access to SUD Treatment – Maria C. Mejia, MD, MPH, FACP

Poster 52 – Services for Treatment of Chronic Pain at Residential Substance Abuse Treatment Centers – Christine Ramladin, PhD

Poster 53 – Adopting a Buprenorphine Precision Dosing Approach Treatment for Hispanic Puerto Ricans – Darlene I. Santiago, PhD, MS

Poster 54 – Pre-Paid Phone Distribution to People With Substance Use Disorder – Alyssa Peterkin, MD; Raagini Jawa, MD, MPH

Poster 55 – The Impacts of the COVID-19 Pandemic on Syringe Service Program Staff Wellbeing – Raagini Jawa, MD, MPH

Poster 56 – The Epidemiology of Pre-Hospital Care for Opioid Overdoses in a US-Border Town – Darien Stratton, MD

Poster 57 – Prescribing Medication Assisted Therapy After Admission For Alcohol Withdrawal Syndrome – Raman D. Krimpuri, MD, MBA

Poster 58 – ASAM Levels of Care in a Specialty OB/GYN Clinic – Ashley Cantu-Weinstein; Lulu Zhao, MD
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td>Adverse Childhood Experiences are Associated with Overdose History in Outpatient SUD Care</td>
<td>Angelo M. Asheh, MD, MPH</td>
</tr>
<tr>
<td>60</td>
<td>Alcohol Use in Primary Care: It's Time to Ask</td>
<td>Stephanie D. Nichols, PharmD, BCPS, BCPP; Mark Publicker, MD; Denise M. O'Connell, MSW, LCSW, CCM, CCP</td>
</tr>
<tr>
<td>61</td>
<td>Impact of an Alcohol Withdrawal Screening and Treatment Protocol for Hospitalized Patients</td>
<td>Brian Schonewlad; Jessica Heil, MSPH; Matthew Salzman, MD</td>
</tr>
<tr>
<td>62</td>
<td>Assessment of COVID-19 Driven Changes in an Integrated OBGYN Addiction Treatment Clinic</td>
<td>Sumaya A. Smarony; Anna Treatment Clinic; Jessica Heil, MSPH; Matthew Salzman, MD</td>
</tr>
<tr>
<td>63</td>
<td>AUD Readmission Risk Lower With Pre-Discharge Ketamine Infusion or Naltrexone Injection</td>
<td>Dale J. Terasaki, MD, MPH</td>
</tr>
<tr>
<td>64</td>
<td>Availability of Buprenorphine-Naloxone in Outpatient Pharmacies in South Florida</td>
<td>Maria G. Rodriguez; Alina Syros, MPH</td>
</tr>
<tr>
<td>65</td>
<td>Beyond Trauma-Informed Care: Insights from a Qualitative Study</td>
<td>Danielle Gainer, MD</td>
</tr>
<tr>
<td>66</td>
<td>Bucinnazine Overdose: A Case Report</td>
<td>Shashi Prabha, MD</td>
</tr>
<tr>
<td>67</td>
<td>Buprenorphine Rapid Microdosing for Opioid Use Disorder Treatment in the Outpatient Setting</td>
<td>Leslie W. Suen, MD, MAS</td>
</tr>
<tr>
<td>68</td>
<td>Change the Conversation: Addiction Mentoring is Key in Palliative Care Training</td>
<td>Katrina S. Nickels, MD; Janet J. Ho, MD</td>
</tr>
<tr>
<td>69</td>
<td>Circumstances Around Cigarette Use After Enforced Smoking Abstinence in an American Prison</td>
<td>Rosemarie Martin, PhD</td>
</tr>
<tr>
<td>70</td>
<td>Clinical Guide to Phenibut: Systematic Review of Intoxication, Withdrawal, and Management</td>
<td>Jeremy Weleff, DO</td>
</tr>
<tr>
<td>71</td>
<td>Cognitive, Behavioral, and Emotional Outcomes of Severe Cannabis Use in Adolescents</td>
<td>Ozge C. Amuk Williams, MD; Rikinkumar S. Patel, MD; William E. Tankersley, MD</td>
</tr>
<tr>
<td>72</td>
<td>Kratom Use in Pregnancy</td>
<td>Kenneth Zoucha, MD; Claudia Moore, MD</td>
</tr>
<tr>
<td>73</td>
<td>Increasing Naltrexone Prescriptions for Hospitalized Patients with Alcohol Use Disorder</td>
<td>Brigid A. Adviento, MD, MPH</td>
</tr>
<tr>
<td>74</td>
<td>Multimodal Pain Management in a Patient Taking Extended-Release Buprenorphine</td>
<td>Brigid A. Adviento, MD, MPH</td>
</tr>
<tr>
<td>75</td>
<td>Pilot Survey of SBIRT and Sexual Activity: Outpatient Providers’Comfort Levels Vary</td>
<td>Michael S. Argenyi, MD, MPH; MSW, AAHIVS</td>
</tr>
<tr>
<td>76</td>
<td>Police Response to Opioid Overdoses: Impact on Future Contacts, Incarceration and Overdose</td>
<td>Alice Zhang, MD</td>
</tr>
<tr>
<td>77</td>
<td>People Who Inhale Stimulants At Risk for COVID-19 and Other Injury</td>
<td>Sarah Casey; Samantha M. Sawyer, MPH; Dinah P. Applewhite, MD</td>
</tr>
<tr>
<td>78</td>
<td>Under One Roof – An Integrated Clinic for SUD and HCV/HIV Treatment</td>
<td>Sarah Hipkens, MD</td>
</tr>
<tr>
<td>79</td>
<td>Interventions Addressing Marijuana Use During Pregnancy: A Systematic Review</td>
<td>Destin Groff; Curtis W. Bone, MD, MHS</td>
</tr>
<tr>
<td>80</td>
<td>Syringe Exchange Services in Primary Care</td>
<td>Paula J. Cook, MD, DFASAM; Corey Orndorff</td>
</tr>
<tr>
<td>81</td>
<td>Low-Barrier Group Medical Visits for Substance Use Disorder</td>
<td>Paula J. Cook, MD, DFASAM</td>
</tr>
<tr>
<td>82</td>
<td>Mothers’ Knowledge, Attitudes, and Perception Regarding Extended-Release Buprenorphine</td>
<td>Miao Lai; Justin Bowman; Nancy Nickman, MS, PhD</td>
</tr>
<tr>
<td>83</td>
<td>Using NCCN Recommended Tool to Screen for Opioid Misuse in Cancer Patients: Are We Overdiagnosing Addiction?</td>
<td>Jelyn Eustaquio; Natalie Moryl, MD</td>
</tr>
<tr>
<td>84</td>
<td>On-Demand, Audio-Only Buprenorphine Initiation During COVID-19</td>
<td>Caroline Wunsch, MD; Liana Lum</td>
</tr>
<tr>
<td>85</td>
<td>Opioid Overdoses During the 2020 COVID-19 Pandemic</td>
<td>Allison Hansen; Pooja Rangan, MBBS, MPH</td>
</tr>
<tr>
<td>86</td>
<td>Outcomes of a Robust Addiction Medicine Curriculum in Undergraduate Medical Education</td>
<td>Cara A. Poland, MD; MEd; Jamie Alan, RPh, PharmD; Lia Bennett, MPH</td>
</tr>
<tr>
<td>87</td>
<td>Patients’ Satisfaction With Methadone and Buprenorphine</td>
<td>Ahmed N. Hassan, MD, FRCP, MPH</td>
</tr>
<tr>
<td>88</td>
<td>Higher Buprenorphine Dose Associated with Treatment Retention at Low-Threshold Clinic</td>
<td>Lea Selitsky, MD; MHP; Megan Buresh, MD</td>
</tr>
<tr>
<td>89</td>
<td>Infective Endocarditis in People Who Use Drugs: A Critical Review of Guidelines</td>
<td>Savitha Racha, MD</td>
</tr>
<tr>
<td>90</td>
<td>Extended-Release Buprenorphine for Opioid Use Disorder: A Cost-Effectiveness Analysis</td>
<td>Juliet Flam-Ross; Alexandra Savinkina, MSPH</td>
</tr>
</tbody>
</table>
Poster 91 – Factors Associated With Non-Fatal Overdose Among Patients Enrolled in the OPTIMA Trial – Hannah E. Crepeault; Lianping Ti, PhD

Poster 92 – Impact of a Pharmacist-Initiated Naloxone Dispensing Program in Community Pharmacies – Julia K. Hunter, MD, MPH, FASAM

Poster 93 – Impact of Prenatal Cannabis Use on Maternal and Neonatal Outcomes – Kristin C. Prewitt, MD, MPH

Award Winner: Best Overall

Poster 94 – In Hospital Addiction Treatment Reduces Readmissions for Patients with Related IE – Kate Roberts, MA, MSW, LCSW; Robyn Jordan, MD, PhD


Poster 96 – Perinatal Opioid Use Disorder: Postpartum Access to Healthcare and Opioid Use Treatment – Casey R. Tak, PhD, MPH; Melinda Ramage, FNP-BC, CARN-AP

Award Winner: Associated Professional

Poster 97 – Physician Assistant Students’ Perceptions of Substance Use Disorders – Sarah Stringer, MPAS, PA-C

Poster 98 – Predispositions of Living with Disability During COVID-19 – Kishan Shah, MD; Karthik Budharaju,

Poster 99 – Prenatal Opioid Use: High Stakes Game In Need of a Team Approach – Michael D. Jacobson, DO, MPH

Poster 100 – Results From a Pilot Study Evaluating a Novel Naloxone Nasal Swab – Michael P. Frost, MD, FACP, DFASAM; Sonnie Kim, PharmD; Natalie R. Budilovsky-Kelley, PharmD

Poster 101 – Right Treatment Right Time: ED MOUD in a Single Safety-Net Hospital System – J. Hunter Scarborough, MD; James P. D’Etienne, MD, MBA

Poster 102 – Rural Versus Urban SSP Utilization in Maine: A Harm Reduction Study – Lisa W. Miller, MD

Poster 103 – Surface Based Morphometry (SBM) in Opioid Use Disorder: A Controlled Study – Abhishek Ghosh, MD, DM

Poster 104 – The New and Dynamic Nature of the Opioid Epidemic – Kyle C. Hopkins, MHA

Poster 105 – Transcranial Electrical Stimulation in Meth Craving: A Mechanistic Dose-Response RCT – Hamed Ekhltiari, MD, PhD

Poster 106 – Trauma, Resiliency, and Longitudinal Treatment Outcomes in a Pediatric MAT Clinic – Spencer M. Gardner, MS

Poster 107 – Treatment Experience of Previously Incarcerated People In Outpatient Methadone Treatment – Marina Gaeta Gazzola; Lindsay M. Oberleitner, PhD

Poster 108 – A Prescription Digital Therapeutic for OUD: 36-Week Real-World Clinical Data – Dan Malone, PhD

Poster 109 – “P.O. Buprenorphine” - An Alternative Method of Buprenorphine Initiation: A Case Report – Edmond Hakimi, DO; Aamani Chava, MD

Poster 110 – Decreased Stigma & Increased Health Equity through SUD Focused Nurse Practitioner Education – Michelle Anderson, DNP, APRN, FNP-BC, FAANP; Gina Clarkson, PhD, APRN, NNP-BC

Poster 111 – Disparities in Naloxone Prescriptions During the COVID-19 Pandemic – Li Li, MD, PhD

Poster 112 – Exploring the Association Between Political Affiliation and Alcohol Control Policies – Victor P. Kekere, MD, MS; Valentine Somto, MD, MPH

Poster 113 – Two Cases of Rapid Titration of Methadone in the Hospital Setting – Clare Landefeld, MD, MS; Ogorchukwu F. Omede, MD
Exhibit Hall Schedule

Great Hall 1-3, Third Floor

THURSDAY, MARCH 31, 2022

8:00 am – 5:00 pm  Registration & Exhibit Set-up
5:30 pm – 7:30 pm  Exhibit Hall Open
5:30 pm – 7:30 pm  Shell-abrate Good Tides! Welcome Back Reception

FRIDAY, APRIL 1, 2022

10:00 am – 5:00 pm  Exhibit Hall Open
10:00 am – 10:30 am  Refreshment Break
11:30 am – 12:45 pm  Lunch Break
2:30 pm – 3:00 pm  Networking Break
4:00 pm – 5:00 pm  Ice Cream Social

SATURDAY, APRIL 2, 2022

10:00 am – 11:30 am  Exhibit Hall Open
10:00 am – 11:30 am  Refreshment Break
11:30 am – 4:00 pm  Exhibit Hall Breakdown

The full exhibit hall floor plan and complete exhibitor profiles are also available on the conference website (https://bit.ly/ASAM2022Exhibits) and in the ASAM Events app.

ASAM Booth Schedule | Great Hall Foyer, Third Floor

THURSDAY, MARCH 31, 2022

3:00 pm - 7:00 pm  Booth Open

FRIDAY, APRIL 1, 2022

8:00 am - 5:00 pm  Booth Open
10:00 am - 10:30 am  Speaker Meeting & Greet - Meet our Opening Plenary Speaker Peter Bruun, MFA, Artist, Educator, Curator. Peter Bruun's original artwork will be available for viewing and purchase during the Meet and Greet.
12:00 pm - 12:45 pm  Social Worker & Counselor Meet-up - Network with fellow social workers and counselors at this informal gathering.
4:00 - 4:45 pm  ASAM Fellow (FASAM) Meet-up - Join other ASAM members that maintain this very important member designation. Don’t forget to wear your “FASAM” name ribbon!

SATURDAY, APRIL 2, 2022

8:00 am - 5:00 pm  Booth Open
12:30 pm - 1:15 pm  Nurses, Nurse Practitioners, and Physician Assistants Meet-Up - Network with fellow nurses, nurse practitioners and physician assistants at this informal gathering.
4:00 pm - 4:30 pm  Students and Ruth Fox Scholars - Join fellow students and our 2022 Ruth Fox Scholars to start building your addiction medicine professional network.

Meet the JAM Editors - Learn more about the ASAM Journal of Addiction Medicine (JAM) and get tips on writing a successful paper.
Abbvie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader.

Abbvie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

Acadia Healthcare  211  6100 Tower Circle Franklin, Tennessee 37067 (615) 861-7581 http://www.acadiahealthcare.com
Acadia provides behavioral health and addiction services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics.

Acadia Healthcare - Treatment Placement  518 Specialists & Wellness Resource Center 7940 N Federal Hwy, Suite 210 Boca Raton, Florida 33487 (954) 405-0903 www.treatmentplacementspecialists.com

AdvancedMD  415  698 West 10000 South South Jordan, Utah 84095 (800) 825-0224 http://www.advancedmd.com
AdvancedMD and the Rhythm Master Suite for addiction medicine unify EHR, practice management and patient engagement technologies within a single platform to simplify tasks and make information more accessible.

Alar Pharmaceuticals Inc.  T3  Rm. 312, 3F., No.19, Keyuan Rd., Xitun Dist. Taichung City, Taichung 407 +886 4 24637115 https://alarpharm.com/
As a new drug development company, Alar focuses on developing long-acting injectables for treating CNS disorders, including opioid use disorder, chronic pain, major depressive disorder, and Parkinson’s disease mainly.

Alcoholics Anonymous  621  475 Riverside Drive, 11th Floor New York, New York 10115 (212) 870-3107 http://www.aa.org

AliveCor, Inc.  620  444 Castro St. Mountain View, California 94041 http://www.alivCOR.com

The American Board of Preventive Medicine (ABPM), an ABMS Member Board, offers certification to physicians in three specialties and four subspecialties, including in the subspecialty of Addiction Medicine.

ACAAM is the proud academic home for addiction medicine faculty and trainees. We support the development of ACGME-accredited addiction medicine fellowships, curriculum, faculty resources, and fellow recruitment.

ASAM CONTINUUM  206  11400 Rockville Pike Suite 200 Rockville, Maryland 20852 (301) 547-4110 http://www.asam.org/asam-criteria/asam-criteria-software/asam-continuum
ASAM CONTINUUM is an electronic assessment tool built from The ASAM Criteria that allows clinicians to leverage a clinical decision support system to assess individuals with SUD and co-occurring conditions.

Atadas, Inc.  100  99 W South Temple Unit 802 Salt Lake City, Utah 84101 (801) 458-5900 http://www.atadasmed.com
Remote monitoring of Medication Assisted Treatment (MAT), The monitoring and management of controlled substances prescribed to patients with opioid use disorder (OUD) are vital components of coordinated, compliant patient care.

Aware Recovery Care  418  1625 S Congress Ave Suite 301 Delray Beach, Florida 33445 (203) 779-5799 http://AwareRecoveryCare.com
Aware Recovery Care is a pioneer in full continuum of home-based care including in-home withdrawal management, Medication-Assisted Treatment (MAT) and management, individual therapy, family therapy, coordinated medical and behavioral healthcare.

BayMark Health Services  217  1720 Lakeshore Drive Suite 117 Lewisville, Texas 75057 (469) 470-4984 http://www.baymark.com
BayMark's addiction treatment programs deliver medically-supervised services for adults in a variety of modalities and settings. As the largest specialty healthcare organization in North America addressing the opioid crisis.

BioCorRx Pharmaceuticals Inc.  306  2390 E. Orangewood Ave Suite 500 Anaheim, California 92806 (714) 462-4880 http://www.biocorrx.com
BioCorRx Pharmaceuticals is a biopharmaceutical company and subsidiary of BioCorRx Inc. specializing in developing treatments for substance use disorder such as BICX104 (implantable naltrexone) for opioid and alcohol use disorders.

C Three Foundation  T10  1620 Medical Ln Suite 209 Fort Myers, Florida 33907 (844) HEL-PTSM http://www.cthreefoundation.org
The C Three Foundation is the nation’s only nonprofit organization dedicated to raising awareness of the Sinclair Method for treating and preventing alcohol use disorder.

CHESS Health  416  333 West Commerce Street Suite 2500 East Rochester, New York 14445 (844) MYC-HESS https://www.chesshealth/ CHESS Health offers evidence-based programs that foster connections on the lifelong journey of recovery.

CoxHealth  T1  1423 N Jefferson Ave Springfield, Missouri 65802 (417) 619-3139 http://www.coxhealth.com
CoxHealth is a physician-led, not-for-profit health system with 6 hospitals and 80+ clinics. We have an excellent Addiction Medicine Physician opportunity with our well-established program in vibrant Springfield, Missouri.

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, and deliver better care.

Emergent is a global life sciences company whose mission is to protect and enhance life, by providing specialty products and contract development and manufacturing services that address public health threats.

EPI / Alpha-Stim  414  2201 Garrett Morris Pkwy Mineral Wells, Texas 76067 (800) 326-7246 http://www.alpha-stim.com
Alpha-Stim® AID is a handheld, prescription medical device that is FDA cleared to treat anxiety, insomnia, and depression. Proven fast, safe and effective. Treatments are done at home in 20 minutes.

Elsevier  606

Exhibitors

![Exhibitors](image-url)
For information about FSAM and updates on our October 2022 FSAM CME Conference in Orlando.

GIA Miami
1501 Biscayne Blvd Suite 200
Miami, Florida 33132
(773) 414-3022
http://www.GIA.miami
GIA Miami is an outpatient mental health and addiction recovery center bridging the gap between neuroscientific research and compassionate mental health care.

Hazelden Betty Ford Foundation
612
RW5
Center City, Minnesota 55012
(651) 235-9269
https://www.hazeldenbettyford.org/
The Hazelden Betty Ford Foundation, the nation’s leading nonprofit treatment provider, is a force of healing and hope for everyone affected by the disease of addiction and mental health conditions.

Hikma Pharmaceuticals USA Inc.
104
200 Connell Drive Suite 4100 - 4th Floor
Berkeley Heights, New Jersey 7922
(972) 897-0650
http://www.hikma.com
Hikma Pharmaceuticals is a recognized leader for multisource pharmaceutical products. Specific to Addiction Treatment, Hikma offers a full line of methadone and buprenorphine products and is excited to offer KLOXXADO.

Indivior
401
10710 Midlothian Turnpike, Suite 430
North Chesterfield, Virginia 23235
(804) 379-1090
http://www.indivior.com/
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Indivior Medical Affairs
421
10710 Midlothian Turnpike; Suite 430
North Chesterfield, Virginia 23235
(877) 782-6966
http://indivior.com/
Indivior Treatment Services, Inc is a global specialty pharmaceutical company at the forefront of providing educational resources and treatment options to healthcare providers and patients who have Opioid Use Disorder or Schizophrenia. Additionally the company is vested in the development of treatment options for other substance use disorders.

iRecoveryUSA
605
4605 Congress Avenue Ste 160
Boca Raton, Florida 33487
(561) 464-5500
http://www.iRecoveryUSA.com
iRecoveryUSA provides virtual comprehensive telemedicine-based MAT treatment services for SUD & co-occurring mental health disorders. Our providers include physicians, nurse practitioners, LCWS’s and LMHC’s. We provide home detox & induction services.

Kaiser Permanente / The Permanente Medical Group, Inc.
419
1800 Harrison St 7th Floor
Oakland, California 94612
(510) 625-4120
http://tpmg.permenante.org
As the largest medical group in the US, The Permanente Medical Group, Inc. offers an extraordinary array of opportunities across every specialty in Northern California.

Labcorp
508
531 S. Spring Street
Burlington, North Carolina 27215
(888) 522-2677
http://www.labcorp.com
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.

Lakeview Health
610
1900 Corporate Square Blvd
Jacksonville, Florida 32216
(904) 899-4500
http://www.lakeviewhealth.com
Lakeview Health is a residential addiction and co-occurring treatment facility offering gender separate facilities to men and women to meet their diverse needs and guide them in their recovery journey.

Landmark Recovery
300
720 Cool Springs Blvd #500
Franklin, Tennessee 37067
(615) 788-9169
http://landmarkrecovery.com/
Landmark Recovery is the fastest growing family-owned treatment center company offering individualized dual-diagnosis treatment, including residential, IOP, PHP, and MAT along with Praxis by Landmark Recovery, serving the Medicaid population.

Lifeskills South Florida
216
1431 SW 9th Avenue
Deerfield Beach, Florida 33441
(954) 673-8868
http://www.lifeskillsouthflorida.com
Since 1991, Lifeskills South Florida has offered comprehensive and individualized treatment programs for men and women ages 18 and over suffering from complex mental health and substance use disorders.

Lochness Medical
310
2775 Broadway Suite 100
Buffalo, New York 14227
(317) 490-9445
http://www.lochnessmedical.com/
Lochness Medical Inc. is a premier distribution company carrying the highest quality point of care diagnostics in the United States while specializing in urine and saliva drug testing.

Mallinckrodt
312
385 Marshall Avenue
Webster Groves, Missouri 63119
(217) 836-1483
http://www.mallinckrodt.com
Mallinckrodt develops, manufactures, and distributes specialty branded and generic pharmaceutical products and therapies, providing a portfolio of specialty generics to treat pain, ADHD, opiate and alcohol addiction, depression and insomnia.

MARR Addiction Treatment Centers
308
2815 Clearview Place
Atlanta, Georgia 30340
(678) 612-6377
http://www.marrinc.org
Established in 1975, we are a clinically driven and gender-separate residential addiction treatment program for adults with substance use and co-occurring disorders.

McLean Hospital
607
115 Mill Street
Belmont, Massachusetts 02478
(800) 906-9531
http://www.mcleanhospital.org
Top ranked in Psychiatry by U.S. News and World Report, McLean Hospital offers exceptional compassionate care for individuals with substance use disorders and co-occurring conditions.

Mission Resiliency at Laurel Ridge Treatment Center
110
17720 Corp. Woods Dr.
San Antonio, Texas 78259
(210) 204-0142
http://laurelridgetc.com
Mission Resiliency is a premiere military specific program with the mission of serving our active-duty military community. The Mission program is exclusively designed to meet the needs of service members.

Mountain Area Health Education Center
320
123 Hendersonville Road
Asheville, North Carolina 28801
(828) 771-3545
http://mahec.net/residency-and-student-info /
Mission Resiliency is a premiere military specific program with the mission of serving our active-duty military community. The Mission program is exclusively designed to meet the needs of service members.

Permanente Medical Group, Inc.
419
1800 Harrison St 7th Floor
Oakland, California 94612
(510) 625-4120
http://tpmg.permenante.org
As the largest medical group in the US, The Permanente Medical Group, Inc. offers an extraordinary array of opportunities across every specialty in Northern California.

Pfizer
540
10710 Midlothian Turnpike; Suite 430
North Chesterfield, Virginia 23235
(804) 379-1090
http://www.pfizer.com
Pfizer is a research-based global biopharmaceutical company committed to developing prescription medicines and vaccines to treat a wide range of medical conditions.

Rapid Microbiologics
319
4605 Congress Avenue Ste 160
Boca Raton, Florida 33487
(561) 464-5500
http://www.rapidmicrobiologics.com
Rapid Microbiologics offers a comprehensive range of services and testing for infectious disease, including comprehensive diagnostic kits.

RW3
Center City, Minnesota 55012
(651) 235-9269
https://www.hazeldenbettyford.org/
The Hazelden Betty Ford Foundation, the nation’s leading nonprofit treatment provider, is a force of healing and hope for everyone affected by the disease of addiction and mental health conditions.

SUD & co-occurring mental health disorders.

The Hazelden Betty Ford Foundation is a leading national nonprofit treatment provider, is a force of healing and hope for everyone affected by the disease of addiction and mental health conditions.

Hikma Pharmaceuticals USA Inc.
200 Connell Drive Suite 4100 - 4th Floor
Berkeley Heights, New Jersey 7922
(972) 897-0650
http://www.hikma.com
Hikma Pharmaceuticals is a recognized leader for multisource pharmaceutical products. Specific to Addiction Treatment, Hikma offers a full line of methadone and buprenorphine products and is excited to offer KLOXXADO.

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Indivior Medical Affairs
10710 Midlothian Turnpike; Suite 430
North Chesterfield, Virginia 23235
(804) 379-1090
http://www.indivior.com/
Indivior Medical Affairs is a global specialty pharmaceutical company at the forefront of providing educational resources and treatment options to healthcare providers and patients who have Opioid Use Disorder or Schizophrenia. Additionally the company is vested in the development of treatment options for other substance use disorders.

iRecoveryUSA provides virtual comprehensive telemedicine-based MAT treatment services for SUD & co-occurring mental health disorders. Our providers include physicians, nurse practitioners, LCWS’s and LMHC’s. We provide home detox & induction services.

Kaiser Permanente / The Permanente Medical Group, Inc. offers an extraordinary array of opportunities across every specialty in Northern California.

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.

Lakeview Health is a residential addiction and co-occurring treatment facility offering gender separate facilities to men and women to meet their diverse needs and guide them in their recovery journey.

Landmark Recovery is the fastest growing family-owned treatment center company offering individualized dual-diagnosis treatment, including residential, IOP, PHP, and MAT along with Praxis by Landmark Recovery, serving the Medicaid population.

Lifeskills South Florida has offered comprehensive and individualized treatment programs for men and women ages 18 and over suffering from complex mental health and substance use disorders.

Lochness Medical is a premier distribution company carrying the highest quality point of care diagnostics in the United States while specializing in urine and saliva drug testing.

Mallinckrodt develops, manufactures, and distributes specialty branded and generic pharmaceutical products and therapies, providing a portfolio of specialty generics to treat pain, ADHD, opiate and alcohol addiction, depression and insomnia.

MARR Addiction Treatment Centers are a clinically driven and gender-separate residential addiction treatment program for adults with substance use and co-occurring disorders.

McLean Hospital is a top ranked in Psychiatry by U.S. News and World Report, McLean Hospital offers exceptional compassionate care for individuals with substance use disorders and co-occurring conditions.

Mission Resiliency at Laurel Ridge Treatment Center is a premiere military specific program with the mission of serving our active-duty military community. The Mission program is exclusively designed to meet the needs of service members.

Mountain Area Health Education Center offers a comprehensive range of services and testing for infectious disease, including comprehensive diagnostic kits.

Pfizer is a research-based global biopharmaceutical company committed to developing prescription medicines and vaccines to treat a wide range of medical conditions.

Rapid Microbiologics offers a comprehensive range of services and testing for infectious disease, including comprehensive diagnostic kits.
| Exhibitors |
|-----------|---|---|---|---|---|
| **Net Success USA**  | 513 | **Prescription Drug Consulting LLC**  | 506 | **RX Destroyer**  | 314 |
| With a global presence and a dedicated team of experienced SEO professionals, Net Success USA has become one of the fastest growing internet marketing companies in the world. | PDC is a consulting practice led by former DEA Agent Dennis Wichern which focuses on DEA and SAMHSA MAT & OTP compliance review services and training. | Progressive PHP is designed for adults facing mental health and/or co-occurring substance use disorders. Emphasis is placed on holistic care to assist patients in achieving their recovery goals. | Rx Destroyer™ is a ready-to-use drug disposal system, utilizing a DEA-approved method of destruction. Rx Destroyer™ accepts solid and liquid medications. | Ophelia is a digital treatment provider for patients with opioid use disorder (OUD). Ophelia removes barriers for the 80% of Americans with OUD who are unable to access evidence-based care. |  |
| **OraSure Technologies**  | 511 | **Progressive PHP of Seaside Healthcare**  | 509 | **Sante Center for Healing**  | 510 |
| OraSure Technologies, the pioneers of oral fluid drug testing and infectious disease testing, including Inteliswab®, a rapid COVID-19 antigen test. OraSure offers both lab-based and rapid drug and alcohol testing. | Q2i, a digital health company, specializes in supplying evidence-based applications that improve recovery from Substance Use Disorder (SUD). Q2i’s OARS+CM solution is born from NIH studies and clinical trials. | Progressive PHP of Seaside Healthcare 102 4020 Lake Worth Road Palm Springs, Florida 33461 (561) 601-4806 http://www.retreathospital.com | Santé Center for Healing provides integrity-driven, evidence-based, and personalized long-term recovery for those suffering from substance use disorders, mental health, trauma, problematic sexual behavior, disordered eating and other compulsive behaviors. |  |
| **Paradigm Labs**  | 221 | **R1 Learning**  | 515 | **Silver Hill Hospital**  | 609 |
| Paradigm is an independent clinical laboratory specializing in clinical toxicology for medication management and substance use disorder treatment facilities. We offer LCMS/MS screening which minimizes need for expensive, definitive testing. |  |  | Founded in 1931, Silver Hill Hospital is a nationally recognized nonprofit psychiatric hospital located in New Canaan, CT, that provides inpatient and residential transitional living programs for adolescents and adults. |  |
| **Park Royal Hospital & North Tampa Behavioral Health**  | 108 | **Retreat Behavioral Health**  | 102 | **Soberlink**  | T8 |
| Park Royal Hospital & North Tampa Behavioral Health offers inpatient & outpatient services for adults age 18 and older living with mental health & substance use disorders. | Retreat provides quality care at our leading mental health and substance use treatment centers, designed to offer patients truly personalized and comprehensive programs that are tailored to their needs. |  |  |  |
| **Pear Therapeutics**  | 601 | **Ria Health**  | 220 | **Social Model Recovery Systems**  | 716 |
| 200 State Street Boston, Massachusetts 2109 (317) 775-8873 http://peartherapeutics.com/ | 1390 Market Street 200 San Francisco, California 94102 312.501.5530 http://riahospital.com |  | 223 E. Rowland Street Covina, California 91723 (626) 332-3145 http://socialmodel.com Social Model Recovery Systems provides treatment services for those whose lives have become unmanageable due to alcohol and drugs and/or whose mental health issues are interfering with leading productive lives. |  |
| Pear Therapeutics is the pioneer in Prescription Digital Therapeutics (PDTs), reSET®, reSET-O®, and Somnyst® use software to treat substance use disorder (SUD), opioid use disorder (OUD), and Chronic Insomnia, respectively. | Ria Health is a Center of Excellence for alcohol treatment - providing a private, evidence-based, successful telehealth program for people who want to change their relationship with alcohol. |  |  |  |
| **Riverside Recovery of Tampa**  | 215 | **Riverside Recovery**  | 215 | **Spark Biomedical Inc**  | 207 |
| 4004 N. Riverside Dr. Tampa, Florida 33603 (727) 204-4442 http://www.rtrampa.com | Riverside Recovery of Tampa is an upscale drug and alcohol treatment center offering a full continuum of care for men and women suffering from addiction & co-occurring mental health disorders. |  | 18208 Preston Road Ste D9-531 Dallas, Texas 75252 844-654-SPRK (7775) http://www.sparkbiomedical.com Spark Biomedical, Inc. is a leading wearable neurostimulation developer devoted to the lifesaving work of eliminating opioid addiction by addressing the full addiction lifecycle, beginning with withdrawal management. |  |  |

www.TheASAMAnnualConference.org
<table>
<thead>
<tr>
<th>Exhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>TruHealing Addiction &amp; Mental Health Treatment</td>
</tr>
<tr>
<td>10019 Reisterstown Rd 301 Owings Mills, Maryland 21117 (855) 807-6237 <a href="http://www.truhealingcenters.com">http://www.truhealingcenters.com</a></td>
</tr>
<tr>
<td>TruHealing Addiction &amp; Mental Health Treatment is a Joint Commission accredited, nationwide network of alcohol addiction, substance use disorder and mental health treatment facilities.</td>
</tr>
<tr>
<td>U.S. Department of Veterans Affairs - Office of Mental Health and Suicide Prevention, Make the Connection</td>
</tr>
<tr>
<td>1321 Duke Street Alexandria, Virginia 22314 (504) 988-7531 <a href="http://medicine.tulane.edu/departments/clinical-sciences/psychiatry/academic-programs/fellowships/addiction-medicine-fellowship">http://medicine.tulane.edu/departments/clinical-sciences/psychiatry/academic-programs/fellowships/addiction-medicine-fellowship</a></td>
</tr>
<tr>
<td>Tulane offers a one-year ACGME Accredited and ABMS sponsored Fellowship in Addiction Medicine. The program provides well-rounded educational and clinical training in the treatment of individuals with substance use disorders.</td>
</tr>
<tr>
<td>UF Health Florida Recovery Center</td>
</tr>
<tr>
<td>4001 S.W. 13th Street Gainesville, Florida 32608 (352) 454-2158 <a href="http://floridaheal">http://floridaheal</a> center.uflhealth.org</td>
</tr>
<tr>
<td>UF Health Florida Recovery Center is the state's premier addiction treatment program, proudly serving patients in the treatment of substance use and mental health disorders for adults.</td>
</tr>
<tr>
<td>United States Drug Testing Laboratories</td>
</tr>
<tr>
<td>1700 S Mount Prospect Rd Des Plaines, Illinois 60018 (847) 375-0770 <a href="http://www.USDTL.com">http://www.USDTL.com</a></td>
</tr>
<tr>
<td>Drug testing services for child protection agencies, Department of Defense, legal services, research, businesses, analytical and forensic laboratories. We lead the industry in fingernail testing, hair testing, and alcohol biomarkers.</td>
</tr>
</tbody>
</table>

**ASAM 53rd Annual Conference | March 31-April 3, 2022**

**Valued Exhibitors**

<table>
<thead>
<tr>
<th>Exhibit#</th>
<th>Company Name</th>
<th>Booth Number</th>
<th>Address/Phone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>T9</td>
<td>Spectrum Health</td>
<td>100 Michigan Street NE Grand Rapids, Michigan 49503 (269) 779-0041 <a href="http://www.spectrumhealth.org">http://www.spectrumhealth.org</a></td>
<td>At Spectrum Health, we share a common passion, our mission, which is the bedrock for all we do: to improve health, inspire hope and save lives.</td>
<td></td>
</tr>
<tr>
<td>T6</td>
<td>Speranza Therapeutics</td>
<td>433 Plaza Real Boca Raton, Florida 33432 (844) 477-3726 <a href="https://www.speranzatherapeutics.com">https://www.speranzatherapeutics.com</a></td>
<td>Speranza Therapeutics S.T. Genesis is an FDA-cleared device that reduces opioid withdrawal symptoms by 93% within the first hour. Worn for 5 days, the device transitions patients through detox.</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>Spero Health</td>
<td>155 Franklin Road Suite 430 Brentwood, Tennessee 37027 (615) 714-9728 <a href="http://www.sperohealth.com">http://www.sperohealth.com</a></td>
<td>Spero Health, is an integrated provider specializing in outpatient care for individuals suffering from SUD. This integrated care model combines physician services, counseling, recovery support, medication management and patient/family education.</td>
<td></td>
</tr>
<tr>
<td>507</td>
<td>The Change Companies</td>
<td>5221 Sigstrom Drive Carson City, Nevada 89706 (888) 889-8866 <a href="http://www.changecompanies.net">http://www.changecompanies.net</a></td>
<td>ASAM and The Change Companies have entered into a collaborative partnership to provide a wide range of products and services for those in behavior change professions.</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>Total Brain</td>
<td>268 Bush Street #2633 San Francisco, California 94104 (614) 600-8161 <a href="http://www.totalbrain.com/providers/">http://www.totalbrain.com/providers/</a></td>
<td>We deliver providers data, efficiencies and outcomes to implement measurement-based, collaborative care. Clinically-validated assessment enables clinicians to assess brain functions to predict patient success, personalize interventions, and track evidence-based outcomes.</td>
<td></td>
</tr>
<tr>
<td>318</td>
<td>TruetoX Laboratories, LLC</td>
<td>50 Rose Place Garden City Park, New York 11040 (516) 741-1501 <a href="http://www.truetoxlabs.com">http://www.truetoxlabs.com</a></td>
<td>Based outcomes. personalize interventions, and track evidence-based, collaborative care. Clinically-validated outcomes to implement measurement-based, collaborative care.</td>
<td></td>
</tr>
<tr>
<td>316</td>
<td>TruHealing Addiction &amp; Mental Health Treatment</td>
<td>10019 Reisterstown Rd 301 Owings Mills, Maryland 21117 (855) 807-6237 <a href="http://www.truhealingcenters.com">http://www.truhealingcenters.com</a></td>
<td>TruHealing Addiction &amp; Mental Health Treatment is a Joint Commission accredited, nationwide network of alcohol addiction, substance use disorder and mental health treatment facilities.</td>
<td></td>
</tr>
<tr>
<td>121</td>
<td>U.S. Department of Veterans Affairs - Office of Mental Health and Suicide Prevention, Make the Connection</td>
<td>1321 Duke Street Alexandria, Virginia 22314 (504) 988-7531 <a href="http://medicine.tulane.edu/departments/clinical-sciences/psychiatry/academic-programs/fellowships/addiction-medicine-fellowship">http://medicine.tulane.edu/departments/clinical-sciences/psychiatry/academic-programs/fellowships/addiction-medicine-fellowship</a></td>
<td>Tulane offers a one-year ACGME Accredited and ABMS sponsored Fellowship in Addiction Medicine. The program provides well-rounded educational and clinical training in the treatment of individuals with substance use disorders.</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>UF Health Florida Recovery Center</td>
<td>4001 S.W. 13th Street Gainesville, Florida 32608 (352) 454-2158 <a href="http://floridahealcen">http://floridahealcen</a> ter.uflhealth.org</td>
<td>UF Health Florida Recovery Center is the state's premier addiction treatment program, proudly serving patients in the treatment of substance use and mental health disorders for adults.</td>
<td></td>
</tr>
<tr>
<td>608</td>
<td>United States Drug Testing Laboratories</td>
<td>1700 S Mount Prospect Rd Des Plaines, Illinois 60018 (847) 375-0770 <a href="http://www.USDTL.com">http://www.USDTL.com</a></td>
<td>Drug testing services for child protection agencies, Department of Defense, legal services, research, businesses, analytical and forensic laboratories. We lead the industry in fingernail testing, hair testing, and alcohol biomarkers.</td>
<td></td>
</tr>
<tr>
<td>208</td>
<td>US WorldMeds, Inc</td>
<td>4441 Springdale Rd Louisville, Kentucky 40241 (866) 750-8796 <a href="http://usworldmeds.com">http://usworldmeds.com</a></td>
<td>US WorldMeds is a pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions &amp; unmet medical needs.</td>
<td></td>
</tr>
<tr>
<td>520</td>
<td>Value-Based RCM</td>
<td>8429 Lorraine Road #409 Lakewood Ranch, Florida 34202 (954) 459-5872 <a href="http://www.vbrcm.com">http://www.vbrcm.com</a></td>
<td>Value-Based RCM offers a fully integrated end-to-end revenue cycle solution for substance use disorder and behavioral health. Providing our clients with the operational stability and financial predictability they are seeking.</td>
<td></td>
</tr>
<tr>
<td>T7</td>
<td>Women for Sobriety, Inc.</td>
<td>PO Box 618 Quakertown, Pennsylvania 18951 (215) 536-8026 <a href="http://womenforsobriety.org">http://womenforsobriety.org</a></td>
<td>With free in-person and online meetings, the WFS New Life Program provides supportive, empowering, secular, and life-affirming principles that address the unique needs and challenges of women in recovery.</td>
<td></td>
</tr>
<tr>
<td>512</td>
<td>Workit Health</td>
<td>3300 Washtenaw Ave. Suite 280 Ann Arbor, Michigan 48104 (734) 292-4020 <a href="http://www.workithealth.com">http://www.workithealth.com</a></td>
<td>Workit Health is a rapidly growing telemedicine B-corporation and the industry leader delivering whole-person addiction treatment at scale. We are a member experience company that happens to provide addiction care.</td>
<td></td>
</tr>
</tbody>
</table>
Board of Directors

William F. Haning III, MD, DLFAPA, DFASAM
President
2021 – 2023

Margaret A. E. Jarvis, MD, DFASAM
Director-at-Large
2019 – 2023

William H. Yarborough, MD, FACP, FASAM
Regional Director, Region VII
2021 – 2025

Brian Hurley, MD, MBA, FAPA, DFASAM
President-Elect
2021 – 2023

Marla D. Kushner, DO, FSAHM, FACOFP, DFASAM
Director-at-Large
2019 – 2023

Teresa Jackson, MD, FASAM
Regional Director, Region VIII
2021 – 2025

Timothy Wiegand, MD, FACMT, FAACT, DFASAM
Vice President
2021 – 2023

Melissa Weimer, DO, MCR, FASAM
Director-at-Large
2021 – 2023

Keyghobad Farid Araki, MD, FRCPC, ABAM, FASAM
Regional Director, Region IX
2021 – 2025

Aleksandra Zgierska, MD, PhD, DFASAM
Secretary
2021 – 2023

Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM
Regional Director, Region I
2021 – 2025

Stephen M. Taylor, MD, MPH, DFASAM
Regional Director, Region X
2021 – 2025

Kenneth I. Freedman, MD, MS, MBA, FACP, AGAF, DFASAM
Treasurer
2021 – 2023

Itai Danovitch, MD, MBA, FAPA, DFASAM
Regional Director, Region II
2021 – 2025

Joseph Garbely, DO, DFASAM
Ex-Officio Chair, Physicians-In-Training Committee

Paul H. Earley, MD, DFASAM
Immediate-Past-President
2021 – 2023

Audrey M. Kern, MD, DFASAM
Regional Director, Region III
2021 – 2025

Michael Fingerhood, MD, FACP, DFASAM
Ex-Officio Chair, Medical Education Council

Anthony P. Albanese, MD, DFASAM
Director-at-Large
2019 – 2023

Shawn Ryan, MD, MBA, FASAM
Regional Director, Region IV
2021 – 2025

Nicholas Athanasiou, MD, MBA, DFASAM
Ex-Officio Chair, Publications Council

Adam J. Gordon, MD, MPH, FACP, DFASAM
Director-at-Large
2019 – 2023

Anika A. H. Alvanzo, MD, MS, FACP, DFASAM
Regional Director, Region V
2017 – 2021

Jeffrey Selzer, MD, DFASAM
Ex-Officio Chair, Public Policy Committee

Nzinga A. Harrison, MD, FASAM
Director-at-Large
2021 – 2023

Emily Brunner, MD, DFASAM
Regional Director, Region VI
2021 – 2025

Julia L. Chang, MS, MBA
Ex-Officio Executive Vice-President
CEO

www.TheASAMAnnualConference.org
ANNUAL CONFERENCE PLANNING COMMITTEE
Anika A. H. Alvanzo, MD, MS, FACP, DFASAM, Chair
Subhadeep Barman, MD, FAPA, FASAM
Susan Kaye Blank, MD, FASAM
Curtis Bone, MD
G. Malik Burnett, MD, MBA, MPH
Marian Currens, CRNP
Itai Danovitch, MD, MBA, FAPA, DFASAM
Jeremiah Fairbanks, DO
Oluwaseun Falade-Nwulia, MBBS, MPH
Michael Fingerhood, MD, FACP, DFASAM
Ruchi Fitzgerald, MD
Sabrina Gill, MD
Gregg Lund, DO, MS, FAAP
Lewis S. Nelson, MD
Kathleen R. Page, MD
Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM
Michael F. Weaver, MD, DFASAM
J. Deanna Wilson, MD, MPH

AGENCY REPRESENTATIVES
Neeraj Gandotra, MD (SAMHSA Liaison)
Deidra Roach, MD (NIAAA Liaison)
Geetha Subramaniam, MD (NIDA Liaison)

ANNUAL CONFERENCE ABSTRACT REVIEWERS
Jamal Aljari, MD
Daniel Cegłowski, MD, MBA
Corrine Dale, MD, PhD
Maya Armstrong, MD
Rachel Wirginis, DO, MBA
Ilana Hull, MD, MSc
Michael Argenyi, MD, MPH, MSW
Francesco Tani, DO
Kento Sonoda, MD, AAHIVS
Samantha Huo, MD
Steven Tate, MD
Julia Nath, MD
Mollie Nisen, MD
Sunny Kung, MD
Lea Selitsky, MD, MPH
Savitha Racha, MD
Megan Zaworski, DO

ASAM CME COMMITTEE AND REVIEWERS
Cara A. Poland, MEd, MD, DFASAM, Chair
Catharina Armstrong, MD
Subhadeep Barman, MD, FAPA, FASAM
Benjamin Bearnot, MD
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
Noel Ilogu, MD, MRCP, DFASAM
Herbert L. Malinoff, MD, FACP, DFASAM
Edwin A. Salsitz, MD, DFASAM

COOPERATING ORGANIZATIONS
National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH); Substance Abuse and Mental Health Services Administration (SAMHSA); and the International Society of Addiction Medicine (ISAM).
ASAM has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians.

Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence based, evaluated for its effectiveness, and is independent of commercial influence.

**ACCME Accreditation Statement**
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**AMA Credit Designation Statement**
The American Society of Addiction Medicine designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**American Academy of Family Physicians (AAFP)**
The AAFP has reviewed The ASAM 53rd Annual Conference and deemed it acceptable for up to 19.50 Live AAFP Prescribed credits. Term of Approval is from 03/31/2022 to 04/03/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**American Academy of Physician Assistants (AAPA)**
This program is not yet approved for CME credit. Conference organizers plan to request 19.5 AAPA Category 1 CME credits from the AAPA Review Panel. The total number of approved credits is yet to be determined.

**American Association Nurse Practitioners (AANP)**
This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 19.5 contact hours of accredited education.

**NAADAC, the Association for Addiction Professionals**
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

**National Board for Certified Counselors ACEP**
The American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. The American Society of Addiction Medicine is solely responsible for all aspects of the programs.

**California Association for Drug/Alcohol Educators (CAADE)**
This educational program is approved by CAADE: #CP40 999 1222

**California Association of DUI Treatment Centers (CADTP)**
This educational program is approved by CADTP: #205

**California Consortium of Addiction Programs and Professionals (CCAPP)**
This educational program is approved by CCAPP: #OS-20-330-1222

**Maintenance of Certification (MOC)**
The ASAM 53rd Annual Conference and 3 pre-courses meet the CME requirements for the following primary boards:
- American Board of Medical Specialties (ABMS)
- American Board of Preventive Medicine (ABPM)
- American Board of Anesthesiology (ABA)
- American Board of Pediatrics (ABP)
- American Board of Internal Medicine (ABIM)
- American Board of Surgery (ABS)
- American Board of Psychiatry and Neurology (ABPN)
- American Board of Addiction Medicine (ABAM)
- Royal College of Physicians and Surgeons of Canada (RCPSC)

*Learners can claim MOC points for pre-courses and posters for the primary boards and organizations listed above*

**Continuing Education Credits (CEUs)**
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

**Disclosure Information**
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Implementing The ASAM Criteria®

The ASAM Criteria is the nation’s most respected, comprehensive, and widely used set of guidelines for determining appropriate levels of care for each patient based on severity and multidimensional needs.

Tools to Support the Implementation of The ASAM Criteria®

**ASAM LEVEL OF CARE CERTIFICATION**

Independent verification of treatment programs’ ability to deliver services consistent with The ASAM Criteria Level of Care standards.

[www.asamcertification.org](http://www.asamcertification.org)

**ASAM CONTINUUM™**

Software for conducting a multidimensional assessment with decision support for level of care recommendations.

[www.asamcontinuum.org](http://www.asamcontinuum.org)

**ASAM CRITERIA COURSE**

Competency-based learning activities to support use of The ASAM Criteria in practice. Both live and e-learning courses available.

[www.asam.org/education](http://www.asam.org/education)

ASAM LEVEL OF CARE CERTIFICATION

Resources to Prepare for Certification:

*The ASAM Level of Care Certification Manual* describes the level of care standards derived from The ASAM Criteria, the rating elements that will be assessed during the certification survey, and the policies, procedures, and systems a program should have in place to meet the standards.

*The ASAM Level of Care Certification Preparation Workbook* outlines the rating elements that will be assessed by certification surveyors and provides a template for programs to conduct self-assessments to identify strengths and areas for improvement.

*The ASAM Criteria* textbook is the authoritative source of the standards for multidimensional assessment, patient placement, and level of care service characteristics for each level of care.

*ASAM Level of Care Certification Training Modules and Webinars* are designed to guide attendees through the standards and rating elements, and describe the path to achieving certification in their organizations, with guidance on avoiding common pitfalls.

Learn more at the ASAM Booth or at these sessions:

**The Next Chapter: A Discussion on the Next Edition of The ASAM Criteria**

Friday, April 1 | 3:00 pm – 4:00 pm | Diplomat Ballroom 3-5, Second Floor

**Development of The ASAM Criteria Intake Assessment: A Free, Paper-Based, Interview Form**

Saturday, April 2 | 4:30 pm – 5:30 pm | Atlantic Ballroom 2&3, Second Floor
ASAM Clinical Practice Guidelines

National Practice Guideline for the Treatment of Opioid Use Disorder 2020 Focused Update

ASAM developed the National Practice Guideline to provide information on evidence-based treatments for opioid use disorder, including all FDA-approved medications.

Pocket guides, apps, CME, Webinars, and more available at:

Clinical Practice Guideline on Alcohol Withdrawal Management

This document is intended to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal. It also provides updated information on evidence-based strategies and standards for care for alcohol withdrawal management in both ambulatory and inpatient settings. This document also addresses current practice concerns and provides clear guidance that will lead to more consistent treatment practices in the field.


Stop by the ASAM Booth to learn more about using these guidelines or how you can get involved in ASAM guideline development.

Learn more about ASAM Clinical Resources Today!
www.ASAM.org/Resources
ASAM Resources


ASAM Weekly is a digital source of timely, useful addiction news, covering everything from treatment practices, addiction research, advocacy, and social issues.

ASAM Principles of Addiction Medicine, 6th edition
For over two decades, The ASAM Principles of Addiction Medicine (PAM) has provided the core knowledge in the specialty field by blending underlying scientific principles with practical essentials of clinical management.

Journal of Addiction Medicine (JAM)
The Journal of Addiction Medicine is a peer-reviewed publication focusing on the latest research developments in addiction medicine, as well as on treatment innovations and ethical, economic, forensic, and social topics.

ASAM Essentials of Addiction Medicine, 3rd Edition
The companion book to Principles of Addiction Medicine, Essentials is streamlined in a concise, easy-to-navigate format for quick reference and access to authoritative information on pharmacology, diagnosis, assessment, and early intervention.

Beyond the Abstract: Addiction Medicine Podcast
An ideal opportunity for readers and others interested in addiction medicine to get a closer look at the perspective behind research articles.

ASAM Handbook of Addiction Medicine, 2nd Edition
Ideal for the general practitioners, this handbook is also an excellent reference for addiction medicine community. Handbook provides practical, evidence-based guidance for identifying and treating substance use disorders.

The ASAM Criteria, 3rd Edition
The most widely used and comprehensive set of guidelines for placement, continued stay and transfer/discharge of patients with addiction and co-occurring conditions that improve the quality of addiction treatment.

ASAM Handbook of Pain and Addiction
The Handbook provides authoritative clinical guidance addressing the complex relationship between addiction and pain. General practitioners and ADM professionals will find this book useful in their practices.

Pocket Addiction Medicine Notebook
A portable reference that can provide key clinical information about vital treatment in addiction medicine seconds.

Visit the ASAM Booth or www.ASAM.org to purchase.
CLAIMING CREDIT:
Claim credit anytime between April 4, 2022 and April 4, 2023.

Full Annual Conference and Pre-Conference Course Registrants:
1. Type https://eLearning.ASAM.org into your web browser.
2. Login to the eLearning Center (eLC), using your ASAM.org username and password (what you used when registering for the conference/pre-conference course).
3. After logging in, select “Dashboard” from the left menu (on mobile devices, you will find “Dashboard” by clicking the three horizontal lines in the header).
4. Locate your Conference or Pre-Conference Course. “ASAM 53rd Annual Conference” will be under “Packages” and the Pre-Conference Courses will be under “On-Demand Products”.
5. Click “Content.” Annual Conference Attendees will also have to find the “Evaluation & Certificate - Live Attendees of ASAM 53rd Annual Conference” and click “View.”
6. Find the box that says “Complete Evaluation” and click the button that says, “Fill out Survey.”
7. After you have completed the evaluation, select the box labeled “Claim Credit & Certificate” and click the button that says, “Claim Medical Credits.”
8. Select your provider type and the number of hours you attended, then click “Submit.”
9. Print out your certificate or save it to your device.

Daily Annual Conference Registrants:
Daily Annual Conference registrants will not claim credit in the ASAM eLC and will receive evaluation and credit instructions via email by April 30, 2022.

WATCHING SESSIONS ON-DEMAND:
Relive the conference or catch sessions you missed! Full registrants of ASAM 53rd Annual Conference and Pain & Addiction: Common Threads receive complimentary access to their sessions on-demand in the ASAM eLearning Center. On-demand sessions will be available from May 1, 2022 - May 1, 2025. Others not registered for the ASAM 53rd Annual Conference or the Pain & Addiction: Common Threads may purchase sessions on-demand in the ASAM eLearning Center when they become available.

The ASAM Motivational Interviewing Workshop and The ASAM Fundamentals of Addiction Medicine Workshop will NOT be recorded or available for online purchase.

eLearning.ASAM.org
National Courses

ASAM REVIEW COURSE in Addiction Medicine
Friday, July 22, 2022 - Sunday, July 24, 2022 | Chicago, IL
reviewcourse.asam.org (Registration Open)

ASAM STATE OF THE ART Course in Addiction Medicine
Thursday, September 29, 2022 - Saturday, October 1, 2022 | Washington DC
stateoftheart.asam.org (Registration Open)

ASAM 54th ANNUAL CONFERENCE
Innovations in Addiction Medicine and Science
April 13-16, 2023 | Washington DC
annualconference.asam.org (Registration Opens August 2022)

Courses Around the Country

The ASAM Criteria Course  |  https://elearning.asam.org/asam-criteria-education
The ASAM Fundamentals of Addiction Medicine  |  https://elearning.asam.org/fundamentals_course
The ASAM Treatment of Opioid Use Disorder Course  |  https://elearning.asam.org/buprenorphine-waiver-course

American Society of Addiction Medicine
11400 Rockville Pike, Suite 200
Rockville, MD 20852
www.ASAM.org